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ABSTRACT 
 
 
 
AN INTERACTION MATRIX OF BTB DOMAIN-CONTAINING 
TRANSCRIPTION FACTORS 
 
 
 
LİYNE NOĞAY 
 
Molecular Biology, Genetics and Bioengineering, MSc Thesis, December 2019 
 
Thesis Supervisor: Prof. Batu Erman 
 
 
Keywords: BTB domain, transcription factors, NCOR/SMRT corepressors, surface 
plasmon resonance, fluorescent two-hybrid assay 
 
 
The Bric-a-brac, Tramtrack, and Broad (BTB) domain is a protein-protein interaction unit 
found in eukaryotes. It forms a distinct multimeric structure with a large interaction 
surface. The exposed residues of each monomer are highly variable and can allow 
dimerization, oligomerization, and interactions with several other proteins such as the 
corepressors nuclear receptor corepressor (NCOR) and silencing mediator of retinoic acid 
and thyroid hormone receptor (SMRT). BTB-containing transcription factors are diverse 
and control various physiological processes ranging from immune system development 
to cell cycle regulation. To understand the structural basis of these functions, we assessed 
the interaction networks of these proteins.  In this study, we developed specific and 
systematic assays to screen the interactions between various BTB domain-containing 
transcription factors and their interaction partners in vitro and in vivo, using surface 
plasmon resonance (SPR) and fluorescent two-hybrid (F2H) assays. We constructed a 
homo- and hetero-dimerization matrix of several BTB domains of interest. 
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ÖZET 
 
 
 
BTB DOMAIN İÇEREN TRANSKRİPSİYON FAKTÖRLERİNİN ETKİLEŞİM 
MATRİKSİ 
 
 
 
LİYNE NOĞAY 
 
Moleküler Biyoloji, Genetik ve Biyomühendislik, Yüksek Lisans Tezi, Aralık 2019 
 
Tez Danışmanı: Prof. Batu Erman 
 
 
Anahtar Kelimeler: BTB bölgesi, transkripsiyon faktörleri, NCOR/SMRT 
eşbaskılayıcıları, yüzey plasmon rezonans, flörosan ikili hibrit tekniği 
 
 
BTB protein bölgesi, ökaryotlarda bulunan bir proten-protein etkileşim birimidir. Geniş 
bir etkileşim alanına sahip, ayırt edici bir üç boyutlu yapıdadır. Dıştaki amino asitleri çok 
çeşitlilik göstermekle birlikte; dimerizasyon, oligomerleşme ve NCOR SMRT gibi 
eşbaskılayıcılarla etkileşim işlevlerine sahip olabilir. BTB sahibi transkripsiyon faktörleri 
çok çeşitlidir ve bağışıklık sistemi gelişiminden hücre döngüsü kontrolüne kadar bir çok 
süreçte rol alırlar. Bu işlevleri tam olarak anlamak için, söz konusu proteinlerin etkileşim 
ağlarının gösterilmesi gerekmektedir. Bu çalışmada, çeşitli BTB bölgesi içeren 
transkripsiyon faktörleri ve onların etkileşim ağlarını, in vivo ve in vitro ortamlarda yüzey 
plazmon rezonansı (SPR) ve flörosan ikili-hibriti (F2H) yöntemlerini içeren, özel ve 
sistematik deneyler geliştirmek amaçlanmıştır. Bu doğrultuda BTB protein bölgelerinin 
kendi içlerinde ve diğer farklı BTB bölgeleriyle gerçekleştirdikleri dimerizasyon 
matrisini oluşturduk. 
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 INTRODUCTION 
 
 
 
1.1. Overview of BTB Domains and Zinc Finger Motifs 
 
 
The BTB domain was firstly discovered in the genome of a DNA virus (poxvirus) as a 
conserved sequence motif (1). Its name is derived from the studies of Laski and his 
colleagues which found that the Drosophila transcription factors Bric-a-brac, Tramtrack, 
and Broad complex all possess an N terminal region whose sequence is similar to the viral 
sequence motif (2,3). Simultaneously, Bardwell and Treisman described a novel zinc 
finger protein, ZID (zinc finger protein with interaction domain) which has a 120 amino-
acid conserved motif at its N terminus and is a large family of poxvirus proteins and zinc 
finger proteins such as GAGA, ZF5 and Ttk. They named this region as POZ (Pox virus 
and Zinc finger) domain (4). These two motifs refer to the same region and are known as 
BTB/POZ domain which is generally abbreviated as the ‘BTB domain’ in a simple way.  
 
BTB domains are evolutionarily conserved protein-protein interaction domains. They 
have ability to establish stable and transient interactions at the same time. Moreover, they 
have evolved to gain new binding functions. Also, the combination of this domain with 
other domains can lead to several distinct functions. In some proteins, the BTB domain 
is coupled with a DNA binding domain to form a dimerizing transcription factors. In other 
proteins, this domain is coupled with ubiquitin ligase domains. Furthermore, it is coupled 
with transmembrane channels as a structural unit (5). 
 
The zinc finger (ZF) motif was firstly discovered in a transcription factor IIIA protein of 
Xenopus laevis (6). The name is derived from the fact that its structure coordinates a zinc 
ion and grasped DNA. This motif has a conserved sequence that contains two cysteines 
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in close proximity to two histidines (C2H2). These four amino acids are necessary to 
coordinate the zinc ion. This consensus sequence is encoded by 3% of all human genes 
and thus it is one of the most common DNA-binding motifs (7). The zinc finger is a 
common evolutionarily conserved DNA binding motif that also has variants that do not 
have the C2H2 structure. The focus of this thesis is the ZBTB transcription factor family 
that has an N-terminal BTB domain and a C-terminal zinc finger DNA binding domain.  
 
 
1.2. Architecture and Functions of BTB Domains 
 
 
The length of BTB domains is about 120 amino acids (4) and these domains are generally 
found as a single copy which is in combination with a variety of other domains. Although 
there are more than 20 different domains that can be found with BTB in proteins, five of 
these are the most commonly observed. These are MATH, Kelch, NPH3, Ion transport 
and Zinc Finger domains (5). Also, some proteins are only composed of a BTB domain. 
For example, Skp1 (involved in the protein degradation)  and ElonginC (involved in the 
regulation of transcriptional elongation) proteins are in this group (8).  
 
To solve the structure of BTB domains, numerous studies used X-ray crystallography. 
Although their primary sequences are not well conserved, the secondary structure and 
tertiary structure and overall architectures of known BTB domain structures are very 
similar (8). This domain is composed of five α-helix cluster which is capped from one 
end by a short three-stranded beta sheet. Its final shape is globular and compact (5).  
 
The fundamental function of BTB domains is to govern protein-protein interactions. The 
functional result of these interactions changes according to the type of their associated 
domain partners (8). For instance, the MATH domain is a member of TRAF-like domain 
which is generally involved in cytoplasmic signal transduction when it is in company with 
BTB domain (9). For the Kelch domain, this partnership can lead to interactions with 
actin filaments through its ß-propeller structure, responsible for providing stability and 
dynamics of actin filaments (10, 11, 12). The BTB-containing proteins associated with 
NPH3 domain are plant specific and involved in phototropism signaling function (13). 
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BTB domain can also be found in ion transport domain containing proteins that form 
voltage gated potassium channels (14). Lastly, BTB-ZF proteins generally function as 
transcription factors that regulate cell survival and differentiation. Although these 
proteins are functionally diverse, they all use their BTB domains for protein-protein 
interactions. However, each different BTB domain has its own behavior during the course 
of these interactions (Figure1.1). For example, BTB domains of BTB-ZF transcription 
factors can homodimerize or heterodimerize and also lead to the recruitment of 
corepressor proteins (15, 16). On the other hand, BTB domains of ion channels, known 
as T1 domain, promote tetramerization (17).  
 
The functional differences of BTB containing proteins originate from two structural 
variations. First, the core BTB domain has extensive sequence variability. The conserved 
part of the sequence is considerably small and most of invariant residues are buried into 
the scaffold of the domain due to their hydrophobic nature while exposed surfaces have 
highly variable residues. The types of residues are the major determinants of the 
oligomerization of this domain and its interaction with other proteins. Secondly, the 
presence of class-specific extensions from either the N or C terminus of the core domain 
are responsible different interactions (8). BTB domains can be classified into the T1, 
Skp1, ElonginC and BTB-ZF families (Figure 1.1). The T1 domain containing proteins 
possess only the core BTB domain. ElonginC does not have the last α-helix of this core 
domain. On the other hand, Skp1 contains two additional helices located at the C terminus 
and this creates a large surface for interactors. Finally, BTB-ZF proteins possess a 25 
amino acid extension at the N terminus of the core domain. The tertiary structure of BTB-
ZF proteins contain an extra beta-sheet and an α-helix. These extra structures contribute 
to dimerization (5). In this study, we studied the dimerization properties of BTB-ZF 
proteins.    
 
 
1.3. Evolution of BTB-Containing Proteins 
 
 
The BTB domain is encoded by the genomes of viruses and eukaryotes ranging from 
fungi to metazoans and plants. Therefore, it is likely that this domain evolved after the 
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origin of eukaryotes (5). Except for Candidatus Protochlamydia amoebophila, it is not 
seen in bacteria or archaeabacteria (18). There is a correlation between the complexity of 
organisms and the number of BTB domain proteins it encodes. The human genome 
encodes more than 350 different BTB-containing proteins. 
 
 
Figure 1. 1 The BTB protein families and their mode of interactions 
Four subtypes of BTB domains are available and they have distinct structures and mode 
of bindings. T1 domain is a BTB domain found in ion channels and it possesses a 
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fundamental core and tetramerizes in the cells. The ElonginC family proteins have a core 
BTB domain lacking the last α-helix. The Skp1 family proteins contain a core domain 
which additionally has two C terminal α-helices. ElonginC and Skp1 are accompanied by 
an adaptor protein, Cul2 and Cul1 respectively, in E3 ubiquitine ligase complexes. Lastly, 
BTB-ZF proteins have the core BTB domain with two additional α-helices at the N 
terminus. Different proteins in this family have ability to dimerize or make complexes 
with other proteins. 
 
 
However, there are some exceptions to this correlation. For instance, the worm C. elegans 
has a large number of BTB-containing proteins in spite of its complexity level (5). Some 
organisms have BTB domains which can only be coupled with certain other domains. For 
example, BTB-NPH3 proteins are only available in Arabidopsis. On the other hand, 
Arabidopsis does not contain BTB-ZF or BTB-Kelch proteins. Similarly, C. elegans has 
a large number of MATH-BTB proteins but no BTB-Kelch and BTB-ZF proteins. It is 
worth noting that MATH-BTB proteins are thought to participate in the defense against 
parasites and therefore under strong positive selection pressure (19). Among all the BTB 
domains, the MATH-BTB proteins are the most common (20).  
 
 
1.4. BTB-Zinc Finger Protein Family 
 
 
The human genome contains 156 genes that encode BTB-containing proteins. Of these, 
49 have C2H2 zinc fingers (Table 1.1) (21) and are named as BTB-ZF. Another name for 
this family is POZ/Krüppel like (POK), which originated from the definition of N-
terminal POZ domain and C2H2 zinc finger Krüppel proteins responsible for segmentation 
in Drosophila (22). Although they are found in the genomes of viruses, BTB-ZF genes 
are restricted to higher eukaryotic genomes, mostly the vertebrates’ (21). Many of the 
genes encoding mammalian BTB-ZF proteins are found in leukemic translocations. ZF 
motifs are DNA binding motifs that provide the sequence specificity of the transcription 
factors. Their BTB domains are responsible for oligomerization and interactions with 
transcriptional regulators. BTB domains can recruit corepressor proteins such as NCOR 
(Nuclear Receptor Corepressor) and SMRT (Silencing Mediator for Retinoid and Thyroid 
Hormone Receptor) (23) as well as activators such as p300 (24). 
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Table 1. 1 List of human BTB-ZF proteins and the numbers of ZF motifs in these 
proteins (21) 
Name (in humans) Synonyms Number of ZFs 
ZBTB1 ZNF909 8 
ZBTB2 ZNF437 4 
ZBTB3  2 
ZBTB4 KAISO-L1, ZNF903 6 
ZBTB5  2 
ZBTB6 ZID, ZNF482 4 
ZBTB7A FBI-1, LRF, pokemon, 
ZBTB7, ZNF857A 
4 
ZBTB7B c-Krox, Th-POK, 
ZBTB15, ZFP67, 
ZNF857B 
4 
ZBTB7C ZBTB36, ZNF857C 4 
ZBTB8A BOZF1, ZBTB8, 
ZNF916A 
2 
ZBTB8B ZNF916B 2 
ZBTB9 ZNF919 2 
ZBTB10 RINZF 2 
ZBTB11 ZNF913 12 
ZBTB12 G10, NG35, Bat9 4 
ZFP161 ZBTB14, ZNF478, ZF5 5 
ZBTB16 PLZF, ZNF145 9 
ZBTB17 MIZ1, pHZ-67, ZNF151, 
ZNF60 
13 
ZNF238 C2H2–171, RP58, TAZ-1, 
ZBTB18 
4 
PATZ1 MAZR, PATZ, RIAZ, 
ZBTB19, ZNF278, ZSG 
7 
ZBTB20 DPZF, ODA-8S, ZNF288 5 
ZNF295 ZBTB21 8 
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ZBTB22 BING1, fruitless, 
ZBTB22A, ZNF297, 
ZNF297A 
3 
GZF1 ZBTB23, ZNF336 10 
ZBTB24 BIF1, PATZ2, ZNF450 8 
ZBTB25 KUP, ZNF46 2 
ZBTB26 ZNF481 4 
BCL6 BCL5, BCL6A, LAZ3, 
ZBTB27, ZNF51 
BAZF, 
6 
BCL6B BAZF, ZBTB28, ZNF62 5 
HIC1 ZBTB29, ZNF901 5 
HIC2 HRG22, ZBTB30, 
ZNF907 
5 
MYNN SBBIZ1, ZBTB31, 
ZNF902 
8 
ZBTB32 PLZP, FAXF, FAZF, Rog, 
TZFP, ZNF538 
3 
ZBTB33 KAISO, ZNF-kaiso, 
ZNF348 
3 
ZBTB34 ZNF918 3 
ZBTB37 ZNF908 3 
ZBTB38 CIBZ, ZNF921 10 
ZBTB39 ZNF922 8 
ZBTB40  ZNF923 12 
ZBTB41 FRBZ1, ZNF924 14 
ZBTB42 ZNF925 4 
ZBTB43 ZBTB22B, ZNF-X, 
ZNF297B 
3 
ZBTB44 BTBD15, ZNF851 4 
ZBTB45 ZNF499 4 
ZBTB46 BTBD4, RINZF, ZNF340, 
zDC 
2 
8 
 
ZBTB47  ZNF651 9 
ZBTB48 HKR3, ZNF85 11 
ZBTB49 ZNF509 7 
ZNF131  6 
 
 
1.4.1. The Modes of Action of BTB-ZF Proteins in Transcriptional Regulation 
 
BTB-ZF proteins are essential transcription factors with roles in biological processes such 
as gastrulation, limb formation, DNA damage response, progression of cell cycle in both 
normal and oncogenic tissues, stem cell pool maintenance, and gamete formation (25). 
Recent studies also revealed the importance of these proteins in the development and 
function of the immune system (26). ZFs bind to DNA in a sequence-specific manner, 
specifically recognizing the regulatory regions of target genes. DNA binding is coupled 
with recruitment of cofactors that are members of chromatin remodeling complexes or 
transcriptional activation/silencing complexes (26).   
 
Cofactor complexes are formed with the mediation of BTB domains.  BTB domains 
directly contact with corepressors and histone modifying enzymes such as SMRT, NCOR 
and Histone deacetylase (HDAC)1, -2, -4, -5 and -7 (27). For example, B-lymphoma 6 
(BCL6) is a member of this family and it is also known as a proto-oncoprotein due to its 
capability to help cancer progression when it becomes oncogenes. BCL6 is able to bind 
to its corresponding specific DNA sequence and leads to the repression of transcription 
via recruiting HDACs through corepressor proteins BCL6 corepressor (BCOR), NCOR 
and SMRT, which are all known as silencers. BCL6 is necessary for germinal center (GC) 
formation because it represses the expression of several genes necessary to sustain 
mutagenic activity without DNA damage response activation or apoptosis with the help 
of this cofactor complex formation. BCL6 proteins in GC does not allow maturation of B 
cells to memory cells or plasma cells to keep de-differentiated state stable by repressing 
the genes responsible for differentiation through corepressor complexes (28, 29, 30, 31). 
 
Addition to recruitment of corepressors, BTB domains facilitate homodimerization or 
heterodimerization between the members of this protein family. For example, BCL6 has 
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ability to homodimerize but also it might heterodimerize with other BTB-ZF proteins 
such as LRF, MIZ1, PLZF and BAZF (32, 33, 34, 35). These homodimerizations or 
heterodimerizations have ability to direct whole transcription factors to the corresponding 
region of DNA and eventually end up with increased binding affinities and distinct 
functions (5). For instance, BCL6-MIZ1 heterodimerization leads to interaction of BCL6 
and MIZ1 proteins which eventually causes repression of CDKN1A cell cycle arrest gene 
so that BCL6 is able to promote proliferative expansion of the germinal center in the 
course of normal immune response (33).  
 
 
1.4.2. The Biological Functions of Selected BTB-ZF Proteins in Transcriptional 
Regulation  
 
There are at least 49 known BTB-ZF proteins in human and they are responsible for 
silencing the expression of corresponding genes in a sequence-specific way. In this study, 
we focused on the most studied and biologically significant members. Their detailed 
physiological functions and structural descriptions are seen in the following subsections. 
 
 
1.4.2.1. B-Cell Lymphoma 6 (BCL6) 
 
The BCL6 protein is encoded by ZBTB27 gene in humans. It is composed of 706 amino 
acids. It has an N-terminal BTB domain and six  C terminal ZF domains (36). These 
domains are responsible for regulation of transcription of target genes in distinct ways 
which have been already mentioned in section 1.4.1. The structure and functions of the 
domains of BCL6 are shown in figure 1.2.  
 
The BCL6 protein was firstly discovered as an oncoprotein in diffuse large B cell 
lymphoma, which is known as the most common non-Hodgkin’s lymphoma type (37). 
This proto-oncoprotein nature of BCL6 originates from its ability to prevent expressions 
of tumor suppressor and cell cycle arrest genes such as p53, CHEK, CDKN1A/p21, and 
ATR (38). The expression of BCL6 protein is highly seen in germinal centers (GC) of B 
cells in which affinity maturation and class switch recombination (CSR) events take 
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place. Its expression is downregulated upon selection for differentiation into memory or 
plasma cells or apoptosis (36). Mice lacking BCL6 were not able to form GC after they 
immunized with the antigens in T-cell dependent way. Furthermore, antigen specific B 
cells of these mice could not undergo affinity maturation and CSR to form their IgG types.  
Finally, they experienced elevated level of inflammation in their certain organs such as 
lung and heart which resulted from  Th2 dependent hyper-immune responses, which 
suggests that BCL6 controls the expression of Th2 cytokines, important for development 
of GC memory B cells and generation of antigen specific T cells (39, 40). Also, BCL6 
promotes the repression of Blimp-1 protein expression, which is a transcription factor 
responsible for plasma cell differentiation (41). Apart from these functions, BCL6 is able 
to prevent cell cycle arrest and apoptosis in the B cells of GC, which provides DNA 
damage to take place under the conditions in which no activation of cell cycle checkpoints 
occurs. This is crucial because after affinity maturation and CSR, DNA damage is the 
result and by repressing p53, ATR, CHEK1 and p21, cell cycle checkpoint activation is 
prevented to sense this damage (42). 
 
 
Figure 1. 2 Structure of BCL6 protein and its physiological functions 
The diagram exhibits the overall architecture of BCL6 protein. BTB domain is 
responsible for protein protein interactions. PEST is a protein sequence composed of 
proline (P), glutamic acid (E), serine (S) and threonine (T) amino acids and known as 
signal peptide for degradation of the whole protein under suitable conditions. The ZF 
motifs are responsible for DNA binding in a sequence specific manner. When BCL6 
homodimerization (or heterodimerization for some cases) occurs, the recruitment of 
corepressors takes place and large corepressor complex is formed. Eventually, certain 
physiological functions are carried out. The crystal structure of BCL6 homodimer is 
visualized by using VMD program.  
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1.4.2.2. Fanconi Anemia Zinc Finger (FAZF) 
 
The FAZF protein is encoded by ZBTB32 gene in humans. It is composed of 487 amino 
acids. It has an N-terminal BTB domain and three C-terminal ZF motifs. It was initially 
discovered as a binding partner of Fanconi Anemia (FA) group C protein (FANCC) (43). 
FA is a disease whose characterization is done by the presence of hypersensitivity to DNA 
crosslinking agents and it is known as either autosomal or X-linked recessive. FA patients 
frequently show bone marrow failure and defects in congenital development. FANCC has 
a region which is necessary for the interaction with FAZF; this interaction is not mediated 
with the BTB domain of FAZF and this region is mutated in the patients (44). FAZF is 
also known as testis zinc finger proteins (TZFP), repressor of GATA (RoG) or PLZF-like 
zinc finger proteins (PLZP). This protein is responsible for the recruitment of histone 
modifying enzymes to regulate the target gene expression. Generally, corepressors such 
as NCOR and HDACs are recruited to the corresponding chromatin region (45).  
 
FAZF shares 68% identity with PLZF and thus it is able to bind to similar DNA sequences 
as PLZF does. Moreover, they have ability to heterodimerize but the physiological roles 
of this heterodimerization is still obscure (43). FAZF can also interact with other 
transcription factors essential in hemopoiesis. For example, FAZF can repress GATA3-
induced cytokine expression that is necessary for T cell lineage development. The 
estimation about this repression is that FAZF can cause direct recruitment of HDAC to 
cytokine promoter and repress interleukin-4 (IL4) expression in CD8+ T cells (46). This 
estimation is compatible with the results coming from knock-out mouse studies. FAZF-
deficient mice showed elevated T lymphocyte proliferation and cytokine production in 
CD8+ and CD4+ T cells. Also, these mice had elevated number of HSCs in G1 phase of 
cell cycle which implies that FAZF possesses roles in cell proliferation event (47). The 
structure and functions of the domains of FAZF are shown in figure 1.3.  
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Figure 1. 3 Structure of FAZF protein and its physiological functions 
The diagram exhibits the overall architecture of FAZF protein. BTB domain is 
responsible for protein protein interactions and ZF motifs are able to bind to DNA in a 
sequence specific manner. When FAZF homodimerization (or heterodimerization for 
some cases) occurs, the recruitment of corepressors takes place and large corepressor 
complex is formed. Eventually, certain physiological functions are carried out. The 
crystal structure of FAZF homodimer is visualized by using VMD program.  
 
 
1.4.2.3. KAISO 
 
The KAISO protein is encoded by ZBTB33 in humans. It has an N-terminal BTB domain 
and three C-terminal ZF motifs; and in total 672 amino acids. It was firstly discovered 
with a yeast-two hybrid experimental setting in which armadillo repeat domain protein (, 
p120 catenin, was used as a bait. According to the interaction map of this system, p120 
catenin bound to the C-terminal 200 amino acids of KAISO and this binding was 
completely independent from BTB domain (48). 
 
The KAISO protein shows bimodal specificity for DNA binding: it is able to bind to the 
consensus sequence TCCTGCNA, known as KAISO binding site (KBS), specifically. 
Also,  it can bind to DNA sequences with methylated CGCG (CpGs) (49). p120 catenin 
binding site is found within the KAISO ZF domain region, thus p120 catenin can inhibit  
DNA binding of KAISO protein when they interact and this leads to abrogation of 
transcription repression mediated by KAISO (50). KAISO generally acts as a 
transcriptional repressor in such a way that first it directly binds to DNA by two of its 
three ZF motifs, then it uses its BTB domain for homodimerization or heterodimerization 
depending on the context. After dimerization, the recruitment of corepressors such as 
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NCOR takes place and further HDAC components are added to this large complex (51). 
On the contrary, between its BTB domain and ZF motifs, there are two highly acidic 
regions available in KAISO protein. Those acidic regions are thought to activate 
transcription of target genes such as neuromuscular gene rapsyn ant this reflects the 
presence of transcriptional activator nature of KASIO (50, 52). The structure and 
functions of the domains of KASIO are shown in figure 1.4. 
 
 
Figure 1. 4 Structure of KAISO protein and its physiological functions 
The diagram exhibits the overall architecture of KAISO protein. BTB domain is 
responsible for protein protein interactions and ZF motifs are able to bind to DNA in a 
bimodal fashion. AR regions are two acidic regions. When KAISO homodimerization (or 
heterodimerization for some cases) occurs, the recruitment of corepressors takes place 
and large corepressor complex is formed. Eventually, certain physiological functions are 
carried out. The crystal structure of KAISO homodimer is visualized by using VMD 
program. 
 
According to previous studies, KAISO is implicated in tumorigenesis. For instance, 
several target genes of KAISO such as MTA2, siamois, cylinD1 and MMP7 are related to 
cell proliferation or tumor metastasis. The target genes of Wnt/β-catenin/TCF, siamois, 
cylinD1 and matrilysin, were exposed to KAISO mediated repression in the luciferase-
reporter assays, which might prove that they are target genes for KAISO (50). 
Furthermore, KAISO was found as one of the direct repressors of target genes in Wnt 
signaling which is an essential pathway for embryonic development and tissue 
regeneration (51). These findings can be interpreted as KAISO is a potential tumor 
suppressor in certain cancer types. Surprisingly, according to one study, the mice which 
were KAISO-deficient were still alive without any detectable developmental 
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abnormalities or tumors (53). This might be due to the fact that the presence of some other 
KAISO-related proteins such as ZBTB4 can compensate KAISO loss in these mice (50). 
 
 
1.4.2.4. Leukemia/Lymphoma Related Factor (LRF) 
 
The LRF protein is encoded by ZBTB7A gene in humans. It is composed of 584 amino 
acids. It has an N-terminal BTB domain and four C-terminal ZF motifs. It is also known 
as Pokemon, FB-1 and OCZF in the literature. It acts as a transcriptional repressor and 
also an proto-oncoprotein which can be associated with malignancy in solid epithelial 
tumors and lymphomas (54). This protein was firstly named as FNI-1 or Factor Binding 
to IST1 because it has ability to bind to the regions located on HIV1 genome and called 
as the inducer of short transcripts (IST) (55). This FBI-1 protein is able to interact with 
itself and also with HIV-1 viral activator, Tat (56). 
 
Later studies have shown that LRF can bind and control the expression of several other 
genes, which have consensus binding sequence for LRF. They can be exemplified as the 
genes coding extracellular matrix collagen type I, II, IX, X and XI; fibronectin, elastin, 
human cartilage oligomeric matrix protein (COMP), alcohol dehydrogenase ADH5, ARF 
tumor suppressor, c-fos and c-myc oncoproteins (57, 58, 54, 55). Furthermore, LRF is 
able to enhance the transcription of the response genes of NF-kB in such a way that it 
facilitates nuclear import and stabilization of this transcription factor and also it blocks 
nuclear export of it. To interact, LRF uses its BTB domain and NF-kB uses its Rel 
Homology Domain (RHD) of p65 subunit (58). Moreover, LRF is able to repress ARF 
tumor suppressor gene (p14ARF in human, p19Arf in mouse) and thus is kind of a central 
regulator in oncogenesis. When LRF is overexpressed, ARF level is reduced and this 
leads to degradation of nuclear p53 and eventually transformation into oncogenicity. On 
the contrary, the reduction in LRF level results in senescence and apoptosis (59). 
 
LRF is known as master regulator in the fate decision of B lymphoid versus T lymphoid. 
According to the literature, when conditional deletions of LRF in HSCs were performed 
to the mice, the numbers of peripheral B cells reduced dramatically, which proves that 
these cells require LRF to progress to the B cell commitment and development. In the 
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same cells, these conditional deletions resulted in extrathymic T cell development in the 
bone marrow. Additional experiments supported that LRF is responsible for suppression 
of Notch-dependent T cell lineage commitment in the lymphoid progenitor cells localized 
in bone marrow. When LRF was absent, genes found in Notch signaling were abnormally 
upregulated in progenitors and this prevented B cell development and triggered the T cell 
development outside of the thymus (60).  
 
Although LRF is highly similar to PLZF, it cannot heterodimerize with PLZF. On the 
other hand, LRF is able to interact with BCL6 when both proteins simultaneously have 
their BTB domains and ZF motifs. However, it has not been properly known that what 
physiological functions appear after this heterodimerization process (32). The structure 
and functions of the domains of LRF are shown in figure 1.5. 
 
 
Figure 1. 5 Structure of LRF protein and its physiological functions 
The diagram exhibits the overall architecture of LRF protein. BTB domain is responsible 
for protein protein interactions and ZF motifs are able to bind to DNA specifically. When 
LRF homodimerization (or heterodimerization for some cases) occurs, the recruitment of 
corepressors takes place and large corepressor complex is formed. Eventually, certain 
physiological functions are carried out. The crystal structure of LRF homodimer is 
visualized by using VMD program. 
 
 
1.4.2.5. Myc-Interacting Zinc Finger Protein-1 (MIZ1) 
 
The MIZ1 protein is encoded by ZBTB17 gene in humans. It is composed of 803 amino 
acids and has an N-terminal BTB domain and thirteen C-terminal ZF motifs. It was firstly 
discovered in a two-hybrid assay experiment as a protein which interacted with c-MYC. 
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The interaction of MIZ1 and MYC is mediated by the part of 50 amino acid stretch of 
MIZ1 that is localized between ZF 12 and 13 thus it is independent from BTB domain 
(61). MIZ1 BTB domain was crystallized as in the tetramer form (62).  
 
MIZ1 is responsible for the regulation of DNA-damage induced cell cycle arrest, cell 
proliferation and development. Due to its interaction with BCL6 and c-MYC, it has 
certain roles in human cancers (62). The interaction of MIZ1 with BCL6 is mediated by 
BTB domains of these proteins. This interaction leads to suppression of CDKN1A gene 
which encodes p21Cip1 protein, responsible for cell cycle arrest. This suppression might 
facilitate the proliferation in germinal centers during normal immune response because 
during this response, extensive DNA damage takes place due to class switching reactions 
and affinity maturation of B cells and there should be an antagonizing response towards 
p53-dependent p21Cip1 protein upregulation. When this system is deregulated, the 
pathological expansion of B cell lymphomas might be seen (63). Furthermore, the 
interaction between MIZ1 and c-MYC targets promoters of several genes and together 
they act as a transcriptional repressor. The best studied promoters belong to the two cell 
cycle inhibitors, p15Ink4b and p21Cip1 and MIZ1-cMYC transcriptional repressor 
complex represses their expressions. Moreover, this complex acts on the tumor 
suppressor and DNA damage-dependent pathways in an interfering way. For all these 
transcriptional repression steps to take place, MIZ1 should bind to the core promoter of 
target gene, interact with c-MYC and have the integrity of its BTB domain (64). The 
structure and functions of the domains of MIZ1 are shown in figure 1.6. 
 
 
Figure 1. 6 Structure of MIZ1 protein and its physiological functions 
17 
 
The diagram exhibits the overall architecture of MIZ1 protein. BTB domain is responsible 
for protein protein interactions and ZF motifs are able to bind to DNA specifically. When 
MIZ1 heterodimerization with BCL6 occurs or the interaction with c-MYC protein takes 
place,  certain physiological functions are eventually carried out. The crystal structure of 
MIZ1 homodimer is visualized by using VMD program. 
 
 
1.4.2.6. POZ/BTB and AT Hook Containing Zinc Finger 1 (PATZ1) 
 
The PATZ1 protein is encoded by ZBTB19 gene in humans. It has an N-terminal BTB 
domain, an A-T hook DNA binding motif responsible for binding to other DNA binding 
structures during its involvement in chromatin remodeling and transcription regulation, 
and seven C-terminal ZF motifs. It has four alternatively spliced versions which are 
composed of 687, 537, 641 and 537 amino acids. It was firstly discovered in a two-hybrid 
screen assay where BTB domain of BACH2 (BTB and CNC Homology) protein was used 
as a bait. This association of BACH2-PATZ1was mediated by their BTB domains. 
PATZ1 is also named as MAZR, MYC-associated Zinc Finger Related, because of having 
ZF motifs similar to the ones in MYC-associated Zinc Finger (MAZ) proteins (65).  
 
PATZ1 is highly expressed in double negative (DN) thymocytes (during early stages of 
T cell development) and then its expression is down-regulated in double positive (DP) 
and CD8+ thymocytes (during later stages of T cell development) (66). In DN thymocytes, 
PATZ1 is recruited to the Cd8 gene loci and bound to the Cd8 enhancer via its ZF motifs. 
Here, it interacts with NCOR through its BTB domain. Eventually, this leads to the 
regulation of chromatin modification at these loci in a negative way so that transcription 
activation does not take place and CD8 expression is repressed at DN stage of T cell 
development. Almost no expression of PATZ1 is seen in the peripheral T cell population 
(67). During these processes, PATZ1 represses the expression of ThPOK (ZBTB7b; 
cKrox), another member of BTB-ZF transcription factor family (68). In addition to 
thymus, PATZ1 is also expressed in fetal liver and bone marrow as well (65). 
 
The functions of PATZ1 are not limited to T lymphocyte development. For instance, this 
protein also acts as a crucial regulator of p53 in such a way that it is able to bind to p53 
by using its negatively charged region localized between the sixth and seventh ZF motifs. 
Eventual the interaction prevents p53 from binding to DNA and the pattern of p53-
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dependent transcription of target genes is altered. Furthermore, PATZ1 proteins have 
sensitivity towards DNA damage and during the early time points of DNA damage, the 
level of PATZ1 stays constant and p53 level rises rapidly. Therefore, they can exist 
together and interact to some extent. Later time of this damage, the level of PATZ1 and 
p53 becomes inversely proportional. The reduction in the PATZ1 level is due to its 
proliferative effects on cells and not controlled by the interaction of these two proteins. It 
has been estimated that ubiquitination-dependent degradation of proteasome system 
might be the mediator of this reduction (69). The interaction also facilitates the expression 
of certain genes, such as BAX, MDM2 and CDKN1A which are controlled by p53, then 
further increases the possibility of apoptosis. This reflects the tumor suppressor nature of 
PATZ1. On the other hand, when p53 is absent, PATZ1 inhibits the same genes and 
triggers the cell survival, which reflects its oncogenic nature. These two conditions 
explain the dependency of PATZ1 function on the cellular context that it is involved (70). 
 
PATZ1 is able to homodimerize and also heterodimerize with other BTB-ZF transcription 
factors such as BACH2 (65) and PATZ2 (71). The structure and functions of the domains 
of PATZ1 are shown in figure 1.7.  
 
 
Figure 1. 7 Structure of PATZ1 protein and its physiological functions 
The diagram exhibits the overall architecture of PATZ1 protein. BTB domain is 
responsible for protein protein interactions, AT Hook and ZF motifs are able to bind to 
DNA non-specific way. When PATZ1 homodimerization occurs or the interaction with 
p53 protein takes place, certain physiological functions are eventually carried out. The 
crystal structure of PATZ1 protein for human is not available. 
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1.4.2.7. POZ/BTB and AT Hook Containing Zinc Finger 2 (PATZ2) 
 
The PATZ2 protein is encoded by ZBTB24 gene. It has an N-terminal BTB domain, A-T 
hook DNA binding motif which is able to interact with minor groove of AT rich 
sequences, eight C-terminal ZF motifs and 697 amino acids in total. PATZ2 protein is not 
properly studied in terms of its function.  
 
ZBTB24 gene is one of the genes mutated in immunodeficiency, centromeric instability 
and facial anomalies (ICF) syndrome. When this gene is mutated in this disease, the 
disease is described as ICF type 2 or ICF2. In this type, serum antibody and circulating 
memory B cell numbers are greatly lower. The other genes which are involved are 
DNMT3B (DNA methyltransferase 3B, ICF1), CDCA7 (cell division associated 7, ICF3) 
and HELLS (helicase, lymphoid-specific, ICF4) (72, 73). Apart from this, the knockdown 
studies of endogenous PATZ2 revealed that there was a decrease in proliferation of 
human B cell line (Raji cells) by blocking the G0/1 to S cell cycle phase progression and 
no apoptosis induction. Moreover, when PATZ2 was downregulated, the expression level 
of interferon regulatory factor 4 (IRF4) and B lymphocyte-induced maturation protein 1 
(Blimp-1), two essential factors responsible for proliferation and differentiation of B 
cells, was increased. All these functions are performed by PATZ2 in an independent way 
from BCL6. These results show that PATZ2 might be considered as one of the 
transcriptional factor important in human B cell function (74). In addition to these, 
according to one study, the mice which were homozygous for a BTB deletion in PATZ2 
are prone to be early embryonic lethal. This might suggest that PATZ2 may have an 
essential function in developmental processes (75). 
 
 
1.4.2.8. Promyelocytic Leukemia Zinc Finger (PLZF) 
 
The PLZF protein is encoded by ZBTB16 gene. It is composed of 673 amino acids and 
has an N-terminal BTB domain and nine C-terminal ZF motifs. It was firstly discovered 
with a chromosomal translocation, t(11;17)(q23;q21), in acute promyelocytic leukemia 
(APL) in which ZBTB16 fused with retinoic acid receptor alpha (RARα) and transformed 
into PLZF-RARα oncogene. In this situation, 455 amino acids from N-terminus of PLZF 
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is fused with RARα (76). Normally, PLZF acts as a transcriptional repressor which is able 
to bind to the promoters of its target genes such as cyclin A and interleukin 3 (IL3) 
receptor α chain with the help of its ZFs (77, 78). Transcriptional repression is performed 
by the recruitment of corepressor proteins such as NCOR, SMRT and Sin3A through 
BTB domain. This eventually brings HDACs to the corresponding promoter region. This 
complex leads to repression of the genes which basically control mammalian embryonic 
development and myeloid differentiation (79). 
 
When PLZF is expressed in the hematopoietic cell lines, it performs several physiological 
functions such as suppressing growth, arresting cell cycle in the G1/S phase and blocking 
the differentiation (80). According to the recent studies, PLZF acts as a crucial regulator 
of innate T cell lineages. Its expression is elevated in immature CD1d-restricted invariant 
natural killer T (iNKT) cells. When there was PLZF deficiency in the mice studied, their 
cells could not undergo thymic expansion and be reduced in the thymus, liver and spleen. 
The iNKT cells of these mice also behaved like conventional naïve T cells and exhibited 
a reduction in their cytokine (IL-4 and IFN gamma) secretion level when stimulated. 
When ectopic expression of PLZF took place, the acquisition of effector or memory T 
cell phenotype and functions was obtained (81). Besides, PLZF might have some effects 
on NK cell function either in a direct or indirect way. One example for this assumption is 
that the deficiency in PLZF interferes with the protection against infection of  Semliki 
Forest virus and this susceptibility was attributed to the decrease level of IFN-induced 
NK cell cytotoxicity (82). Furthermore, since the expression level of PLZF is high in 
multipotential precursors of hematopoietic cells and low in their differentiated versions, 
PLZF is speculated to be involved in the contribution of embryonic stem cell maintenance 
in the germline (83). Moreover, PLZF is responsible for the patterning of limb and 
skeleton formation by regulating the expression of bone morphogenic proteins and Hox 
gene family whose function is controlling the limb morphogenesis. This patterning is 
modulated by apoptosis and cell proliferation processes in structures of limb (25). The 
structure and functions of the domains of PLZF are shown in figure 1.8.   
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Figure 1. 8 Structure of PLZF protein and its physiological functions 
The diagram exhibits the overall architecture of PLZF protein. BTB domain is responsible 
for protein protein interactions, a proline rich region, and ZF motifs are able to bind to 
DNA specifically. When PLZF homodimerization (or heterodimerization for some cases) 
occurs, the recruitment of corepressors takes place and large corepressor complex is 
formed. Eventually, certain physiological functions are carried out. The crystal structure 
of PLZF homodimer is visualized by using VMD program. 
 
 
1.4.2.9. ZBTB4 
 
ZBTB4 is composed of 1013 amino acids. It has an N-terminal BTB domain which is 175 
amino acid in length but it is interrupted by 60 amino acid-long stretch which is found 
between α helix 3 and beta sheet 4 so that this region is not in the dimerization interface. 
It was firstly discovered as a methyl-DNA binding protein when a BLAST experiment 
was carried out on the human genome against KAISO. ZBTB4 has a bimodal specificity 
to bind DNA as in the case for KAISO, which is able to bind both TCCTGCNA consensus 
sequence and methylated CGCG sequences. However, there is a variation related to their 
binding pattern: while ZBTB4 can bind to a single methylated CpG, KAISO needs at least 
two consecutives methylated CpGs to bind. ZBTB4 is expressed highly in the brain and 
here it is estimated to control the gene expression pattern of different neurons that can be 
involved in olfactory, motor or hippocampal functions (84). In addition to these, ZBTB4 
is able to heterodimerize with MIZ1, which together represses P21CIP1 expression and 
thus leads to inhibition in the cell cycle arrest in response to the activation of p53. On the 
contrary, when there is loss of ZBTB4 in the cellular context, apoptosis is inhibited, cell 
cycle arrest and long-term survival are facilitated in response to the activation of p53 (85). 
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1.5. BACH1 and BACH2 Proteins 
 
 
BTB and CNC homology 1 and 2 (BACH1 and BACH2) proteins are members of basic 
region-leucine zipper family (bZip) of transcription factors. They have an N-terminal 
BTB domain and a C-terminal bZip domain for DNA binding. They are only found in the 
vertebrates and able to bind to Maf-recognition elements (MAREs) (86). BACH2 is 
essential for both innate and acquired immunity and has critical roles in the fundamental 
events of early B cell development such as immunoglobulin class switching, affinity 
maturation of immunoglobulin-encoding genes, the checkpoint of pre-B cell antigen 
receptor, the activation of tissue resident macrophages and the development of effector 
and regulatory T cells (87). On the other hand, BACH1 proteins are responsible for 
producing reactive oxygen species, providing heme homeostasis, involving in cell cycle 
and hematopoiesis as a regulator, the differentiation of erythrophagocytic and 
inflammatory macrophages (88). 
 
The BACH1 protein is able to homodimerize in such a way that it has a novel homodimer 
interaction surface. This homodimerization surface was discovered to contain a novel 
hydrogen bond network and an interaction between hydrophobic surfaces belonging to 
the kinked N-terminus (N-hook) and C-terminal residues of the partner.  When N-hook 
was deleted, the conversion of homodimer into monomer in solution was the result and 
this suggests that the presence of N-hook contributes to the homodimerization of BACH1 
BTB domain (89). On the other hand, the BACH2 protein is able to interact with its target 
genes by using its basic leucine-zipper region. The BTB domain part of it is responsible 
for the recruitment of corepressors and further HDACs. The BTB dimer of BACH2 
resembles the BTB dimers of BTB-ZF transcription factors, this dimerization is 
independent from the N-hook region which is required for the dimerization of BACH1 
protein. The BACH2 protein has been crystallized in two forms: the difference between 
them was the presence of an inter-subunit disulfide bond. This disulfide bond formation 
might be considered as a reversible regulation mechanism during the activity of proteins 
found in oxidative stress responses. Also, the stabilization of the interactions among 
subunits in a protein can be achieved with this bond formation. Furthermore, it can be 
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helpful for the mediation of protein-protein interactions but not required for the 
stabilization of the dimerization surface of BACH2 (90).  
 
 
1.6. Fluorescent Two Hybrid (F2H) Assay 
 
 
Fluorescent two-hybrid (F2H) assay is a novel method to detect and visualize protein-
protein interactions more accurately in the natural environment of living mammalian 
cells. The result of this method is obtained during real time as a simple optical readout. 
The obtained optical readout can be analyzed to acquire the high-quality data for the 
screening of corresponding protein-protein interactions in response to any external stimuli 
or chemical compounds such as inhibitors. This system is basically dependent on the fact 
that a fluorescently labeled bait protein is immobilized on a distinct subcellular structure, 
generally nucleus of the cells, and the detection of interactions between proteins is 
performed by checking the colocalization of another fluorescently labeled prey protein, 
which should be different in terms of its fluorophore, at this defined structure (91). In 
other words, if the proteins, which are freely drifting within the cells, interact with the 
certain components of the cells, which are immobilized and enriched at a specific 
structure in a transient way, colocalization might be eventually observed. In the F2H assay 
system that we used for this study, the BHK cell line clone number 2 which have been 
stably integrated with about 200-1000 copies of a plasmid each possessing 256 copies of 
the lac operator sequence was used (92). On this lac operator, the GFP binding protein 
(GBP)-Lac repressor (LacI) fusion protein sits via its lac repressor part. GBP is a 
nanobody, which is able to bind to GFP and some GFP variants such as YFP with high 
affinity, and it is suitable for expression and localization in vivo conditions. Its molecular 
weight is 13 kDa and it is a soluble protein (93, 94). The GFP-tagged bait protein is 
immobilized by binding of GBP to GFP. If there is an interaction between GFP-tagged 
bait protein and RFP-tagged prey protein, the colocalization of green and red foci is 
observed. This interaction is easily visualized with a conventional fluorescent 
microscopy. F2H assay might give some false positive or negative results thus from the 
beginning it should be controlled. If prey proteins are able to bind to lac operator in the 
absence of bait protein, then they will be only used as baits for further experiments. The 
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most significant advantage of this system is that it is fairly simple because there is no 
need for costly instrumentation or advanced technical expertise (92). The summary of 
F2H assay is seen in figure 1.9.  
 
 
 
Figure 1. 9 Fluorescent Two Hybrid (F2H) assay 
In the genetically modified BHK cells, lac operators are stably integrated into the genome. 
On this region, anchor protein, which is also known as GBP-Lac repressor fusion protein, 
is tethered. GFP-tagged bait protein is bound to this region and this initial localization is 
mediated by GBP-GFP binding, which is visible as a green fluorescent spot in the nuclei 
of transfected cells. If RFP-tagged prey protein is able to interact with the bait protein, it 
will become enriched at the same spot and this results in the colocalization of green and 
red foci. If there is no interaction, only green focus colocalization is seen (not shown). 
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2. AIM OF THE STUDY 
 
 
 
The BTB domains found in BTB-zinc finger transcription factors exhibit how a family of 
fundamental protein domains can form a variety of interactions and eventually acquire 
several distinct functions. These interactions and their networks should be revealed 
properly to understand the mechanisms of related biological processes at a molecular 
level. Previously conducted studies have shown the presence of several BTB homodimers 
but only a few BTB heterodimers. Furthermore, these studies have also revealed that 
certain BTB homodimers are necessary for the repression activity of the BTB-ZF 
transcription factors. Simply, these homodimers form an interface that is essential for the 
interactions with some corepressors such as NCOR, BCOR, and SMRT which are 
members of large histone deacetylase-containing complexes. Therefore, to get an overall 
representation of how BTB domains interact, a more credible and effective way of 
interaction mapping is required. In this study, we aimed to develop an assay for screening 
the interactions between various BTB-ZF transcription proteins and their networks with 
other proteins in a systematic way.  
 
In the first part of the study, we wanted to express and purify the BTB domains of selected 
proteins from the bacterial system. For protein expression, we followed cytoplasmic 
expression protocol by using the Rosetta DE3 pLYSs expression strain of E.coli. The 
purification of these expressed proteins was carried out by immobilized metal affinity 
chromatography (IMAC) and size exclusion chromatography (SEC) respectively.  After 
these purification steps, we designed a surface plasmon resonance (SPR) experiment with 
the obtained proteins to screen their homodimerization, heterodimerization, 
homotetramerization and heterotetramerization potentials.  
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In the second part of the study, we set up a fluorescent two-hybrid assay to identify 
potential homodimers and heterodimers of BTB domains and their interaction networks 
with other corepressor proteins such as NCOR and SMRT. In this assay, BTB domains 
of selected proteins were tagged with two different fluorescent proteins, TagGFP and Tag 
RFP. When there was homo/heterodimerization between the BTB domains with different 
tags, two distinguishable fluorescent foci at the same location within the nuclei of BHK 
cells were formed. Moreover, NCOR and SMRT proteins were tagged with BFP protein 
and the interaction between BTB dimers and these corepressors was checked with the 
designed system. If there was an interaction among them, green and blue foci (TagGFP-
TagGFP homodimers and corepressor) or green, red and blue foci (TagGFP-TagRFP 
homodimers and corepressor) formation at the same spot was the end result. In 
conclusion, our aim for this study was to come up with a high-throughput interaction 
assay to analyze BTB domain interaction networks systematically. This interaction 
network can be further used to identify key residues of BTB interaction interfaces, reveal 
the rules of BTB domain interactions and understand the structure-function relationship 
of BTB-ZF transcription factors. 
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3. MATERIALS & METHODS 
 
 
 
3.1. Materials 
 
 
3.1.1. Chemicals 
 
All the chemicals used in this thesis are shown in Appendix A. 
 
 
3.1.2. Equipment 
 
All the equipment used in this thesis is shown in Appendix B. 
 
 
3.1.3. Solutions and Buffers 
 
Calcium Chloride (CaCl2) Solution: 60 mM CaCl2 (from 1 M stock), 15% glycerol and 
10 mM PIPES (pH 7.0) were mixed and volume of mixture was completed to 500 ml with 
ddH2O. The solution was sterilized with 0.22 µM filter and stored at 4°C. 
 
Agarose Gel: In order to prepare 100 ml 1% w/v agarose gel, 1 g of agarose powder was 
weighed and dissolved in 100 ml 0.5X TBE buffer by heating in a microwave. 0.002% 
(v/v) ethidium bromide was added to the final solution. 
 
Tris-Borate-EDTA (TBE) Buffer: In order to prepare 1 L 5X stock solution, 54 g Tris-
Base, 27.5 g boric acid, and 20 ml 0.5 M EDTA (pH 8.0) were dissolved in 1 L ddH2O. 
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The solution is stored at room temperature and diluted 1 to 10 with ddH2O to obtain 0.5X 
working solution.  
 
Polyethyleneimine (PEI) Solution: In order to prepare 1 mg/ml (w/v) working solution, 
100 mg polyethyleneimine powder was dissolved in 100 ml ddH2O by heating at 80°C. 
The pH was adjusted to 7.0 with 33% hydrochloric acid (HCl). The final solution was 
filter-sterilized, aliquoted as 1 ml in each 1.5 tube and kept at -20°C. 
 
SDS Separating Gel: In order to prepare 10 ml 10% separation gel, 3.34 ml Acrylamide: 
Bis-acrylamide (37.5:1), 2.5 ml Tris (1.5 M pH 8.8), 100 µl 10% (w/v) SDS, 100 µl 10% 
(w/v) APS and 10 µl TEMED were mixed and the volume was completed to 10 ml with 
ddH2O.  
 
SDS Stacking Gel: In order to prepare 5 ml 4% stacking gel, 1.25 ml Tris (0.5M pH 6.8), 
1 ml Acrylamide: Bis-acrylamide (37.5:1), 50µl 10% SDS (w/v), 15µl 10% APS (w/v), 
and 7.5µl TEMED were mixed and the volume was completed to 5ml with ddH2O. 
 
SDS Running Buffer: Initially, 1 L 10X Tris-Glycine stock solution was prepared by 
dissolving 40 g Tris-Base and 144 g Glycine in ddH2O while arranging the pH to 8.3. 
Then, in order to prepare 1X SDS running buffer, 100 ml Tris-Glycine solution was mixed 
with 895 ml ddH2O and 5 ml 20% SDS solution.  
 
Protein Loading Buffer: In order to prepare 4X protein loading buffer, 2.4 ml Tris (1 M 
pH 6.8), 0.8 g SDS, 4 ml 100% glycerol, 0.01% bromophenol blue, and 2 ml β-
mercaptoethanol were mixed and then the volume was completed to 10 ml.  
 
Lysis Buffer: In order to prepare 50 ml 1X lysis buffer, 50 mM HEPES, 250 mM NaCl, 
0.5 mM TCEP, 10 mM imidazole, EDTA-free protease inhibitor cocktail (Roche), and 
10 µl DNase I (100U/ µl) were mixed. The volume was completed to 50 ml with ddH2O. 
 
Buffer IMAC-A: In order to prepare 1 L of IMAC-A solution, 50 mM HEPES, 250 mM 
NaCl, and 10 mM imidazole were mixed. The volume was completed to 1 L with ddH2O. 
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The solution was filter-sterilized and kept at 4°C. 0.5 mM TCEP was added freshly before 
using the solution. 
 
Buffer IMAC-B: In order to prepare 1 L of IMAC-B solution, 50 mM HEPES, 250 mM 
NaCl, and desired concentration of imidazole were mixed. The solution was filter-
sterilized and 0.5 mM TCEP was added fresh before using the solution. The IMAC-B 
solution was used as elution buffer of His-Tagged Affinity Chromatography. In this study, 
100 mM and 300 mM imidazole concentrations were used.  
 
Gel Filtration Buffer: In order to prepare 1 L gel filtration buffer, 20 mM HEPES, and 
250 mM NaCl were mixed. 5 mM TCEP (or 0.05% β-mercaptoethanol) was added to the 
solution. The volume was completed to 1 L with ddH2O.  
 
 
3.1.4. Growth Media 
 
Luria Broth (LB): In order to prepare 1 L 1X LB medium, 20 g LB powder was completed 
to 1 L with ddH2O. The medium was autoclaved at 121°C for 15 minutes. After cooling 
the medium, kanamycin at final concentration of 50 µg/ml, ampicillin at final 
concentration of 100µg/ml or chloramphenicol at final concentration of 34µg/ml was 
added to the liquid medium just before use for antibiotic selection. 
 
LB-Agar: In order to prepare 1 L 1X agar medium, 35 g LB-Agar powder was completed 
to 1 L with ddH2O. The medium was autoclaved at 121°C for 15 minutes. After cooling 
down the medium to 50°C, the corresponding antibiotic was added into the medium for 
selection. The final concentrations of used antibiotics were kanamycin 50 µg/ml, 
ampicillin 100 µg/ml and chloramphenicol 34 µg/ml. 15 ml of LB-Agar solution was 
poured into a sterile petri dish under fume hood. The plates were kept at 4°C. 
 
DMEM: BHK cells were maintained in DMEM growth medium which is supplemented 
with 10% heat-inactivated fetal bovine serum (FBS) and 1% Pen-Strep (100 U/ml 
Penicillium and 100 µg/mL Streptomycin). 
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Freezing Medium: The cells were frozen in heat-inactivated fetal bovine serum 
containing 10% DMSO (v/v).  
 
 
3.1.5. Molecular Biology Kits  
 
All the used commercial molecular biology kits in this thesis are given in Appendix C.  
 
 
3.1.6. Enzymes 
 
Restriction and DNA modifying enzymes, polymerase enzymes, and their corresponding 
buffers were obtained from either New England Bioblabs (NEB) or Fermentas. 
 
 
3.1.7. Bacterial Strains 
 
Escherichia coli (E. coli) DH-5α was used for general transformation and cloning 
applications. E. Coli Rosetta2 DE3 pLysS expression strain was used for mammalian 
protein production and purification.  
 
 
3.1.8. Mammalian Cell Lines 
 
BHK: BHK21 cell line was derived from the kidneys of Syrian hamsters. The BHK cell 
line version we used (ChromoTek) was modified in such a way that cells have Lac 
operator repeats in their genomes.  
 
 
3.1.9. Plasmid and Oligonucleotides 
 
All the plasmids used in this thesis are listed in Table 3.1. 
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Table 3. 1 List of plasmids 
PLASMID NAME PURPOSE OF USE SOURCE 
 
pET-47b (+) The bacterial expression 
plasmid to express BTB 
domains with an N-
terminal His-tag 
Merck Millipore 
(71461) 
pET-47b (+)-BCL6-BTB The bacterial expression 
plasmid to express BCL6-
BTB domain with an N-
terminal His-tag 
Lab construct 
pET-47b (+)-FAZF-BTB The bacterial expression 
plasmid to express FAZF 
BTB domain with an N-
terminal His-tag domain 
with an N-terminal His-tag 
Lab construct 
pET-47b (+)-KAISO-BTB The bacterial expression 
plasmid to express 
KAISO-BTB domain with 
an N-terminal His-tag 
Lab construct 
pET-47b (+)-LRF-BTB The bacterial expression 
plasmid to express LRF-
BTB domain with an N-
terminal His-tag 
Lab construct 
pET-47b (+)-MIZ1-BTB The bacterial expression 
plasmid to express MIZ1-
BTB domain with an N-
terminal His-tag 
Lab construct 
pET-47b (+)-PATZ2-BTB The bacterial expression 
plasmid to express 
PATZ2-BTB domain with 
an N-terminal His-tag 
Lab construct 
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pET-47b (+)-PLZF-BTB The bacterial expression 
plasmid to express PLZF-
BTB domain with an N-
terminal His-tag 
Lab construct 
pCDNA3.1/ myc- His (-) 
B 
Mammalian expression 
plasmid with CMV 
promoter 
Thermo Fischer Scientific, 
(V85520) 
pcDNA3.1/myc-His (-) B-
TagGFP 
The mammalian 
expression plasmid to 
express. N-terminal 
TagGFP  
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP 
The mammalian 
expression plasmid to 
express N-terminal 
TagRFP  
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-BACH1-BTB 
The mammalian 
expression plasmid to 
express BACH1-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-BACH2-BTB 
The mammalian 
expression plasmid to 
express BACH2-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-BCL6-BTB 
The mammalian 
expression plasmid to 
express BCL6-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-KASIO-BTB 
The mammalian 
expression plasmid to 
express KASIO-BTB 
Lab construct 
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domain with N-terminal 
TagGFP tag 
pcDNA3.1/myc-His (-) B-
TagGFP-LRF-BTB 
The mammalian 
expression plasmid to 
express LRF-BTB domain 
with N-terminal TagGFP 
tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-MIZ1-BTB 
The mammalian 
expression plasmid to 
express MIZ1-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-PATZ1-BTB 
The mammalian 
expression plasmid to 
express PATZ1-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-PATZ2-BTB 
The mammalian 
expression plasmid to 
express PATZ2-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-PLZF-BTB 
The mammalian 
expression plasmid to 
express PLZF-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagGFP-ZBTB4-BTB 
The mammalian 
expression plasmid to 
express ZBTB4-BTB 
domain with N-terminal 
TagGFP tag 
Lab construct 
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pcDNA3.1/myc-His (-) B-
TagRFP-BACH1-BTB 
The mammalian 
expression plasmid to 
express BACH1-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-BACH2-BTB 
The mammalian 
expression plasmid to 
express BACH2-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-BCL6-BTB 
The mammalian 
expression plasmid to 
express BCL6-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-FAZF-BTB 
The mammalian 
expression plasmid to 
express FAZF-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-KAISO-BTB 
The mammalian 
expression plasmid to 
express KAISO-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-LRF-BTB 
The mammalian 
expression plasmid to 
express LRF-BTB domain 
with N-terminal TagRFP 
tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-MIZ1-BTB 
The mammalian 
expression plasmid to 
express MIZ1-BTB 
Lab construct 
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domain with N-terminal 
TagRFP tag 
pcDNA3.1/myc-His (-) B-
TagRFP-PATZ1-BTB 
The mammalian 
expression plasmid to 
express PATZ1-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-PATZ2-BTB 
The mammalian 
expression plasmid to 
express PATZ2-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B-
TagRFP-PLZF-BTB 
The mammalian 
expression plasmid to 
express KAISO-BTB 
domain with N-terminal 
TagRFP tag 
Lab construct 
pcDNA3.1/myc-His (-) B- 
GBP-LacI 
The mammalian 
expression plasmid to 
express GBP-LacI fusion 
protein for F2H assay 
Lab construct 
pcDNA3-GFP GFP expressing plasmid 
for transfection control 
Lab construct 
pCDNA3.1/myc-His (-) B-
BFP-oligo1-NCOR 
The mammalian 
expression plasmid to 
express oligo1-Ncor with 
N-terminal TagBFP tag 
Lab construct 
pCDNA3.1/myc-His (-) B-
BFP-oligo1-SMRT 
The mammalian 
expression plasmid to 
express oligo1-SMRT 
with N-terminal TagBFP 
tag 
Lab construct 
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pcDNA3.1/myc-His (-) B- 
BFP-NLS 
The mammalian 
expression 
plasmid to express N-
terminal TagBFP 
Lab construct 
 
All the oligonucleotides used in this thesis are listed in Table 3.2. 
 
 
Table 3. 2 List of oligonucleotides 
OLIGONUCLEOTIDE 
NAME 
SEQUENCE PURPOSE 
OF USE 
 
BCL6-BTB-SmaI-
Forward 
TGGACTCGAGATGGCCTCGCCGGC
TGACAG 
pET-47(b)+ 
cloning 
BCL6-BTB-NotI-
Reverse 
GGACGCGGCCGCTTATTCACTGGC
CTTAATAAACTTCCGGCAAG 
pET-47(b)+ 
and F2H  
cloning  
FAZF-BTB-SmaI-
Forward 
TGGACCCGGGATGTCCCTGCCCCC
CATAAGACTGC 
pET-47(b)+ 
cloning 
FAZF-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAAGCCCTGTC
CCCTCGAGCCCTC 
pET-47(b)+ 
and F2H  
cloning 
KAISO-BTB-SmaI-
Forward 
TGGACCCGGGATGGAGAGTAGAA
AACTGATTTCTGC 
pET-47(b)+ 
cloning 
KAISO-BTB-NotI-
Reverse 
GGACGCGGCCGCTTACTGTGACAA
TGGGACACCAA 
pET-47(b)+ 
and F2H  
cloning 
LRF-BTB-SmaI-Forward TGGACCCGGGATGGCCGGCGGCGT
GGA 
pET-47(b)+ 
cloning 
LRF-BTB-NotI-Reverse GGACGCGGCCGCTTAGATCTGCCG
GTCCAGGAGGTCG 
pET-47(b)+ 
and F2H  
cloning 
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MIZ1-BTB-SmaI-
Forward 
TGGACCCGGGATGGACTTTCCCCA
GCACAGCCAGC 
pET-47(b)+ 
cloning 
MIZ1-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAAGCAAGTGA
CTTGAGGGCATGGCAG 
pET-47(b)+ 
and F2H  
cloning 
PATZ2-BTB-SmaI-
Forward 
TGGACCCGGGATGGCAGAAACATC
GCCAGAG 
pET-47(b)+ 
cloning 
PATZ2-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAGCTATGATT
ATTTTGGAAGTCTGTGTAAGC 
pET-47(b)+ 
and F2H  
cloning 
PLZF-BTB-SmaI-
Forward 
TGGACCCGGGATGGATCTGACAAA
AATGGGCATGA 
pET-47(b)+ 
cloning 
PLZF-BTB-NotI-
Reverse 
GGACGCGGCCGCTTACTGGATGGT
CTCCAGCATCTTCAG 
pET-47(b)+ 
and F2H  
cloning 
PATZ1-BTB-XhoI-
Forward 
TGGACTCGAGGGATGGAGCGGGTC
AACGACGCTTC 
F2H  
cloning 
PATZ1-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAGGACTGTTT
GATTACTTCCTGGCAGATC 
F2H  
cloning 
PATZ2-BTB-XhoI-
Forward 
TGGACTCGAGGGATGGCAGAAAC
ATCGCCAGAG 
F2H  
cloning 
PLZF-BTB-XhoI-
Forward 
TGGACTCGAGGGATGGATCTGACA
AAAATGGGCATGA 
F2H  
cloning 
LRF-BTB-XhoI-Forward TGGACTCGAGGGATGGCCGGCGGC
GTGGA 
F2H  
cloning 
KAISO-BTB-XhoI-
Forward 
TGGACTCGAGGGATGGAGAGTAG
AAAACTGATTTCTGC 
F2H  
cloning 
ZBTB4-BTB-XhoI-
Forward 
TGGACTCGAGGGATGCCCCCCCCT
GCAGAGGTGACG 
F2H  
cloning 
ZBTB4-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAACCAGGCAG
TGCGAGCCGGGCGCT 
F2H  
cloning 
BCL6-BTB-XhoI-
Forward 
TGGACTCGAGGGATGGCCTCGCCG
GCTGACAG 
F2H  
cloning 
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BACH1-BTB-SmaI-
Forward 
TGGACCCGGGATGTCTCTGAGTGA
GAACTCGGTTTTT 
F2H  
cloning 
BACH1-BTB-XhoI-
Forward 
TGGACTCGAGGGATGTCTCTGAGT
GAGAACTCGGTTTTT 
F2H  
cloning 
BACH1-BTB-NotI-
Reverse 
GGACGCGGCCGCTTAAAATTTCAG
AAACTGAAAGCAGGATTCCTC 
F2H  
cloning 
BACH2-BTB-SmaI-
Forward 
TGGACCCGGGATGTCTGTGGATGA
GAAGCCTGACT 
F2H  
cloning 
BACH2-BTB-XhoI-
Forward 
TGGACTCGAGGGATGTCTGTGGAT
GAGAAGCCTGACT 
F2H  
cloning 
BACH2-BTB-NotI-
Reverse 
GGACGCGGCCGCTTACAGGAAGCT
GAAGCAGGAGTCCT 
F2H  
cloning 
CMV Forward  CGC AAA TGG GCG GTA GGC GTG F2H  
cloning 
TagGFP-XhoI&SmaI-
Reverse 
GGACCTCGAGGGACCCCGGGAGA
ACCGCTGTACAGCTCGTCCATGCC 
F2H  
cloning 
 
 
3.1.10. DNA and Protein Molecular Weight Markers 
 
DNA and protein ladders which were used in this thesis are given in Appendix E. 
 
 
3.1.11. DNA Sequencing 
 
DNA sequencing services were provided by MCLAB, CA, USA. 
(https://www.mclab.com/home.php). 
 
 
3.1.12. Software, Computer-based Programs, and Websites 
 
Software, computer-based programs, and websites used in this thesis are given in Table 
3.3 
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Table 3. 3 List of software and computer-based programs and websites 
SOFTWARE, 
PROGRAM, 
WEBSITE NAME 
COMPANY/WEBSITE PURPOSE OF 
USE 
 
CLC Main 
Workbench v7.9.4 
QIAGEN Bioinformatics Molecular cloning, 
analysis of 
sequence, data, 
DNA sequence 
alignment 
NCBI BLAST https://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
Tool for basic local 
alignment to 
examine the 
similarities 
between biological 
sequences 
NCBI PRIMER-
BLAST 
https://www.ncbi.nlm.nih.gov/tools/prime
r-blast/ 
 
Primer design 
Addgene https://www.addgene.org/ 
 
Information for 
plasmid map 
ExPASy https://www.expasy.org/ 
 
Protein parameters 
and translation tool 
Ensembl Genome 
Browser 
https://www.ensembl.org/index.html 
 
Information for 
Human genome 
UNICORN 7.1 GE Healthcare Life Sciences Chromatography 
operation 
BIACORE T200 
software v3.0 
GE Healthcare Life Sciences Operation and 
Evaluation of SPR 
experiments 
Visual Molecular 
Dynamic (VMD) 
https://www.ks.uiuc.edu/Research/vmd/ 
 
Analysis of PDB 
files 
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3.2. Methods 
 
 
3.2.1. Bacterial Cell Culture 
 
 
3.2.1.1. The growth of Bacteria 
 
E.coli DH5α and Rosetta DE3 pLYSs strains were cultured in LB medium with 
corresponding antibiotics for selection, overnight around 12-16 hours at 37°C with 
vigorous shaking (221rpm). To obtain single bacterial colony, the culture was spread with 
autoclaved glass beads on LB-Agar plates containing the suitable antibiotics for selection 
and these plates were incubated overnight at 37°C. In order to prepare glycerol stock, 
10% (v/v) glycerol was added to the bacterial culture to get 1 ml final volume under the 
fume hood. Cryovials were used to maintain glycerol stocks and they are kept at -80 °C. 
 
 
3.2.1.2. Preparation of Competent Bacteria 
 
Previously prepared competent E.coli DH5α was added to 40 ml LB in a 250 ml flask 
without adding any antibiotics due to the absence of resistance in this strain. The culture 
was incubated overnight at 37°C by shaking at 221 rpm (For Rosetta2 DE3 pLYSs, 
chloramphenicol with a final concentration of 34µl/ml was added at this stage.). The next 
day, 4 ml of overnight-grown culture was taken from 40 ml initial culture and inoculated 
into 400 ml LB in 2 L flask without the addition of any antibiotic. This final culture was 
incubated at 37°C with vigorous shaking (221 rpm) until the optical density of the culture 
at 590 nm (OD590nm) has reached to 0.375. After this point, 400 ml culture was divided 
into eight sterile 50 ml tubes and they were incubated on ice for 10 minutes. Then, this 
chilled bacterial culture was centrifuged at 1600 g for 10 minutes at 4°C. The supernatant 
was removed and each bacterial pellet was resuspended in 10 ml ice-cold CaCl2 solution 
and then centrifuged at 1100 g for 5 minutes at 4°C.  Again, the supernatant was discarded 
and each pellet was resuspended in 10 ml ice-cold CaCl2 solution.  The cells were 
incubated on ice for 30 minutes. Then, they were centrifuged at 1100 g for 5 minutes at 
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4°C. The supernatant was discarded and each pellet was resuspended in 2 ml pre-chilled 
CaCl2 solution. All the suspensions were put together in one 50 ml tube and aliquoted as 
200 µl volume for each ice-cold microcentrifuge tube. They were immediately flash-
frozen in liquid nitrogen at -80°C and kept at -80°C. The transformation efficiency of 
prepared competent cells was calculated by transforming different concentrations of 
pUC19 plasmid (Efficiency should be between 107-108 cfu/µg).  
 
 
3.2.1.3. Transformation of Competent Bacteria 
 
For all transformation experiments, heat-shock transformation was carried out. Flash 
frozen aliquots of chemically competent bacteria were thawed on ice until they turned 
into viscous form. Then, desired concentration of DNA (for pure plasmid transformation, 
1pg-1ng; for ligated product transformation, 5-20 µl ligation mix) was added into 
competent bacteria. The mixture was incubated on ice for 30 minutes. After this 
incubation, the cells were heat-shocked at 42°C for 90 seconds and placed on ice for 1 
minute. 800 µl LB (without addition of any antibiotic) was put on the heat-shocked cells 
and this final culture was incubated at 37°C for 45 minutes. After this incubation, the cells 
were centrifuged at 13,200 rpm for 30 seconds and bacterial pellet was resuspended in 
100 µl of LB coming from the supernatant. Finally, this suspension was spread onto LB-
agar plate containing the corresponding antibiotic for selection and the plates were 
incubated overnight at 37°C. 
 
 
3.2.1.4. Plasmid DNA Isolation 
 
In order to isolate plasmid DNA from E.coli DH5α, alkaline lysis protocol as described 
in Molecular Cloning: A Laboratory Manual (Sambrook et at.) was carried out. 
Furthermore, Macherey Nagel Midiprep commercially available kit was performed 
according to protocol of manufacturer for midiprep protocol. The obtained concentration 
and purity of DNA were measured by a NanoDrop spectrophotometer.  
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3.2.2. Mammalian Cell Culture 
 
 
3.2.2.1. Maintenance of Cell Lines 
 
For maintenance of BHK cells, complete DMEM was used. This maintenance was 
performed in 10 cm sterile tissue culture plates and those plates were incubated in the 
incubator whose temperature and CO2 level were set to 37 °C and 5% CO2 respectively. 
When cell confluency reached to about 80%, the cells were split in such a way that cells 
were firstly washed with serum-free DMEM, trypsin was added afterwards and they were 
waited in trypsin for 5 minutes within the incubator. Then, they were suspended in 
complete DMEM and split to a new 10 cm sterile tissue plate at 1:10 ratio. This process 
should be repeated for every 2-3 days.  
 
 
3.2.2.2. Cryopreservation of Cells 
 
Cells were frozen within the freezing medium for later use or storage purposes. They were 
split a day before freezing to become 30-40% confluent. The next day, cell were counted 
to obtain 1-5x106 cells. Then, they were centrifuged at 300 g for 5 minutes. Pelleted cells 
were resuspended in 1 ml freezing medium and kept in the cryovials. The cryovials were 
put into a freezing container which has isopropanol and stored at -80°C for at least 24 
hours and then transferred to liquid nitrogen tank for long-term storage.  
 
 
3.2.2.3. Thawing Frozen Mammalian Cells 
 
Cryovials were initially taken out from nitrogen tank. Then, cells were immediately 
thawed by addition of 9 ml complete growth medium (DMEM for this study) in 15 ml 
centrifuge tube to dilute DMSO found in the freezing medium. The cells were centrifuged 
at 300 g for 5 minutes to remove DMSO. The supernatant was taken out, pellet was 
resuspended in 10 ml complete growth medium and suspension was placed in 10 cm 
tissue culture plate. Plate was incubated at 37°C and 5% CO2.  
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3.2.2.4. Transient Transfection of Mammalian Cell Lines Using Polyethyleneimine 
 (PEI) 
 
The day before transfection, the necessary number of cells were split onto 6-well tissue 
culture plate. On the transfection day, desired amount of DNA (2 µg for this study) was 
mixed with 200 µl serum-free phenol-free DMEM in a sterile microcentrifuge tube. Then, 
PEI (1 µg/µl) solution was vortexed well and added to DNA-DMEM mix at a 2:1 ratio of 
PEI (µg) to total plasmid DNA (µg). Immediately after addition of PEI, the mixture was 
vortexed and incubated at room temperature for 15 minutes. After incubation, the mixture 
was added onto the cells in a dropwise manner. The list of PEI transfection ingredients 
and conditions for 6 well plate is shown in Table 3.4. 
 
Table 3. 4. List of PEI transfection ingredients and conditions 
Plate Type Seeded cell 
number 
DMEM 
amount for 
cell seeding 
Total DNA 
amount 
DMEM 
amount for 
transfection 
PEI:DNA 
ratio 
6 well plate 1.5x105 2 ml 2 µg 200 µl 2:1 
 
 
3.2.3. Vector Construction 
 
Restriction enzyme digestion: Digestion reactions were carried out by mixing desired 
amount of DNA, corresponding enzymes and their compatible buffers in PCR tubes. It 
was followed by incubation in Thermal Cycler for 1-3 hours at the optimum temperature 
of corresponding enzymes.  
 
Klenow fragment application: Klenow fragment was used for blunting of DNA via filling 
the 5’-overhangs created by XhoI restriction enzyme digestion in cloning steps of BTB-
domains to pcDNA3.1/myc-His (-) B-TagRFP-BTB domains.  
 
Dephosphorylation of 5’ phosphate groups: When the plasmid DNA is digested with a 
single enzyme or compatible enzymes and further aimed to be used in a ligation reaction, 
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5’ phosphate groups of linearized plasmids are removed by alkaline phosphatase enzyme 
(calf intestinal alkaline phosphatase, (CIAP)) in order to prevent self-ligation.  
 
Agarose gel electrophoresis and DNA purification from the gel: PCR products, products 
of digestion reactions and other DNA samples are separated and visualized with the help 
of agarose gel electrophoresis. Agarose gels were prepared by dissolving the required 
amount of agarose which is determined according to the size of DNA fragment, ranging 
from 0.7 to 2 g, in 100 ml 0.5X TBE. The prepared mixture was heated in a microwave 
to dissolve the agarose completely. Then, it was cooled down and 2 µl ethidium bromide 
(0.0002% v/v) was added to this final solution. DNA samples were mixed with DNA 
loading dye and loaded to the already solidified agarose gel. Electrophoresis was carried 
out at 100 V for 45-90 minutes in 0.5X TBE buffer. As a next step, gel extraction is 
performed to obtain the corresponding DNA band which was cut from the gel under UV 
light quickly to minimize the harmful effects of UV light. DNA was then purified with 
the help of a commercially available gel purification kit according to the manufacturer’s 
protocol. 
 
Ligation:  Ligation reactions are carried out by the use of T4 DNA Ligase (NEB) with its 
suitable buffer. For all ligation experiments, 1:3 vector to insert ratio was chosen. 100 ng 
vector DNA was used with the required insert amount for ligation reactions. Ligation was 
carried out either at room temperature for 2 hours or at 16°C for 16 hours. For each 
cloning, vector-only ligation was additionally done as a control to check whether there 
was re-ligation of the vector on itself or not. Finally, the ligation mixture was transformed 
into E. coli DH5α competent cells. 
 
 
3.2.4. Protein Purification 
 
 
3.2.4.1. Bacterial Expression Vector Construction 
 
As a backbone, pET-47b (+) bacterial expression vector with an N-terminal His-tag was 
used. The BTB domains of selected proteins were obtained as in the form of PCR products 
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by using Q5 High-Fidelity DNA Polymerase (NEB) according to its suggested conditions 
for PCR. In order to amplify these inserts, the forward primers with SmaI and the reverse 
primers with NotI restriction sites were designed. SmaI and NotI-HF enzymes do not 
work in Q5 Reaction Buffer hence NucleoSpin Gel and PCR Clean-up protocol was 
carried out just before digestion of PCR products. The suitable annealing temperature for 
PCR was determined by performing gradient PCR. Reactions were carried out in a 
thermal cycler by using Q5 High Fidelity DNA Polymerase according to following recipe; 
 
5X Q5 Reaction Buffer 5 µl 
10 mM dNTPs 0.5 µl 
10 µM Forward Primer (SmaI-BTB Domain Forward) 1.25 µl 
10 µM Reverse Primer (BTB Domain- NotI- Reverse) 1.25 µl 
Template DNA (1 ng) 1 µl 
Q5 High-Fidelity DNA Polymerase (2,000 units/ml) 0.25 µl 
ddH20 To 25 µl 
 
In order to construct the desired vector, the vector backbone and inserts were digested 
with SmaI at 25°C for 2 hours then with NotI-HF at 37°C for 1 hour. 
 
 Insert pET-47b (+) 
DNA PCR product 2 µg 
10X CutSmart Buffer (NEB) 5 µl 5 µl 
SmaI (20,000 U/ml) (NEB) 1 µl 1 µl 
NotI-HF (20,000 U/ml) (NEB) 1 µl 1 µl 
ddH2O To 50 µl To 50 µl 
 
Then, CIAP enzyme (Fermentas) treatment was applied to the digested pET-47(+) vector 
backbone, which was PCR cleaned-up after digestion (elution to 30 µl), to prevent re-
ligation of vector on itself.  
 
SmaI and NotI-HF digested pET-47b (+) 30 µl 
CIAP Enzyme (20,000U/ml) (Fermentas) 3 µl 
10X CIAP Buffer (Fermentas) 5 µl 
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ddH2O To 50 µl 
 
The CIAP enzyme was applied at 37°C for 30 minutes. Then, the obtained vector was run 
on a 1% agarose gel to separate the double-digested vector from the uncut vector. The 
corresponding band was extracted from the agarose gel and the DNA was purified. To 
obtain the digested insert, the reaction mixture was purified with NucleoSpin Gel and 
PCR Clean-up kit. The ligation reaction was performed according to 3:1 insert to vector 
ratio. After ligation, transformation into E. coli DH5α competent cells was performed. 
Single bacterial colonies were picked from LB-Agar plate and their plasmid DNAs were 
isolated with miniprep protocol. The accuracy of ligation was controlled by performing 
diagnostic digestions and possible correct candidates were sent to sequencing. 
 
 
3.2.4.2. His-tagged Protein Expression 
 
pET-47b (+) plasmid has all the necessary features for protein expression and purification 
such as the presence of T7 promoter, lac operator, LacI gene, N-terminal His-tag, 3C 
protease recognition site, and kanamycin resistance gene for selection. LacI protein binds 
to the lac operator in such a way that it eventually prevents the transcription from the T7 
promoter. However, when the addition of IPTG to the medium happens, this IPTG 
competes with LacI protein and inhibits the prevention of transcription. N-terminal His-
tag is necessary to perform affinity chromatography. 3C protease recognition site is 
important if N-terminal His-tag is necessary to be removed.  
 
Initially, pET-47b (+)-BTB domain (for BCL6, FAZF, KAISO, LRF, MIZ1, PATZ2, and 
PLZF BTBs) plasmids were transformed into E. coli Rosetta2 DE3 pLYSs competent 
cells. Rosetta2 DE3 strains are derived from the BL21 strain. They are specifically 
designed to express eukaryotic proteins that contain rarely used codons in bacteria. In this 
strain, extra tRNAs for rare codons and their corresponding promoters are available. The 
backbone of the rare tRNA-coding vector also has a chloramphenicol resistance gene. 
Furthermore, the presence of DE3 indicates this strain is a λDE3 lysogen which refers 
that a prophage is found as DNA expressing the T7 RNA polymerase gene under the 
lacUV5 promoter control and protein production happens with the help of IPTG 
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induction. pLYSs strains produce T7 lysozyme which provides protein purification in a 
controllable way by preventing T7 RNA polymerase basal expression. Thanks to this, 
leakage in protein production can be reduced. 
 
 
Figure 3. 1 Bacterial induction and expression of His-tagged proteins
 
After transformation, a single colony was randomly picked and inoculated into 3 ml LB 
medium which was added with 3 µl of Chl and Kan antibiotics. This preculture was 
incubated at 37°C for 6-8 hours with vigorous shaking (221 rpm). Then, it was transferred 
to 25 ml LB culture in which 25 µl Chl and Kan were also supplemented. This culture 
was incubated overnight at 37°C with vigorous shaking (221 rpm). Finally, 25 ml 
preculture was transferred to 1 L LB medium. This time, antibiotic concentration dropped 
to 40% of the general working concentration to decrease resistance effect on cells, 
promote cell growth and production of protein. This last culture was incubated at 37°C 
with vigorous shaking (221 rpm) until its optical density at 600 nm (OD600nm) was in 
between 0.4-0.6. When this range was reached, culture was incubated on ice to cool down 
and then IPTG was added in such a way that final concentration should be 0.1-0.2 mM. 
Induction of protein expression was performed with the help of IPTG addition by 
incubating the culture overnight at 18°C in a shaker incubator (180 rpm). (Figure 3.1). 
 
 
 
Incubate at 37°C for 6-8 hours
in 3 ml preculture
with Chl & Kan
Incubate at 37°C o/n
in 25ml pre-culture
with Chl & Kan
Incubate at 37°C in 1L culture until 
OD reaches 0.4-0.6 for LB 
(antibiotic concentration 40% of 
general working concentration)
Add IPTG (0.1-0.2 mM final 
concentration)
Incubate at 18 ° C o/n 
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3.2.4.3. Affinity Chromatography of His-tagged Proteins 
 
Harvesting of cells was performed at 4000 rpm for 10 minutes and the supernatant was 
discarded. Then, the pellet was dissolved in 25 ml lysis buffer which should be freshly 
prepared. The cells were lysed by sonication using Qsonica Q500 at 4°C in a box filled 
with ice. For sonication, total elapsed time was arranged to 4 minutes and 30 seconds, 
and pulse was on for 5 seconds and off for 10 seconds. The final cell lysate was spun at 
15000 rpm for 45 minutes at 4°C. Meanwhile, the affinity column was washed with 
ddH2O and checked whether it is plugged or not. For cell lysate of 1 L culture, 3 ml 
HisPur Cobalt Superflow Agarose resin was loaded to the column. The resin solution is 
diluted 1:1 in ethanol thus the actual volume of resin added was 1.5 ml. The resin was 
washed with ddH2O two times to get rid of ethanol and then washed with 10 ml of IMAC-
A two times to equilibrate the column. When centrifugation was completed, the 
supernatant containing soluble proteins was loaded to the column and the protein-resin 
mixture was incubated with end-to-end rotation at 4°C for about 30 minutes. After this 
incubation, flow through was collected in a 50 ml tube. This collected fraction includes 
the proteins without His-tag. Then, the resin-protein complex was washed with 10 ml of 
IMAC-A for three times. Finally, the His-tagged protein was eluted by the use of IMAC-
B solutions with different concentrations. Starting from the lowest imidazole 
concentration, IMAC-B solutions were loaded to column and fractions were collected in 
15 ml tubes at 4 °C (Figure 3.2). 
 
 
Figure 3. 2 Steps of immobilized metal affinity chromatography (IMAC) 
Lysis of the cell Centrifugation at 15000 rpm
at 4°C for 45 min
Loading of 
supernatant
Co
Incubation
of His-tagged 
BTB domains
with resin
for 10 min at 4°C
Pellet with
insoluble proteins 
Washing with
low imidazole 
concentration
(10 mM)
Elution with
high imidazole
concentration
(100 mM)
His-tagged BTB domain
Cellular Proteins
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3.2.4.4. SDS-PAGE gel and Coomassie Blue Staining 
 
Preparation of 14% separating gel and 4% stacking gels was performed and the samples 
from each protein purification step, which can be listed as cell lysate, after sonication, 
pellet, non-retained fraction and elutes, were mixed with 4X protein loading buffer. 
Denaturation of those samples were carried out at 95 °C for 10 minutes. When the samples 
were loaded to the wells, they were run with 1X running buffer for about 2-2.5 hours. 
After running, the gel was separated from the glasses carefully and the stacking gel was 
removed as well. Then the remaining gel was placed into the staining solution for 2-3 
hours and then into the destaining solution overnight. 
 
 
3.2.4.5. Concentrating Proteins 
 
When the protein is too diluted, it is concentrated with the help of concentrator tubes 
which have a specific molecular weight cut-off value. If size of protein is smaller than 
this cut-off value, the protein will pass to the bottom. Otherwise, it will stay at the top. 
Initially, ddH2O was put into the concentrator tube and spun at 3000 g until all the water 
went down. Then, the protein of interest was added, spun for 1 minute and protein 
concentration was measured by NanoDrop. For this measurement, the liquid passed to the 
bottom of the tube was used as a blank. Concentrator falcon was spun for several times 
at 3000 g until concentration or volume of protein reached to desired values. For this 
study, the used concentrator tubes had 10 kDa or 5 kDa molecular weight cut-off.  
 
 
3.2.4.6. Size-exclusion Chromatography 
 
When there are some other non-specific proteins in the eluted version of total protein 
sample after His-tag affinity chromatography, size exclusion chromatography is carried 
out to remove non-specific proteins from the desired protein according to their size 
differences. AKTA pure was used as size exclusion chromatography. Superdex 200 
Increase 5/150 GL and Superdex 200 Increase 10/300 GL columns were used during the 
procedure. Gel filtration buffer was used for the equilibration of the column. Before this 
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equilibration, washing of the pumps and column with autoclaved filtered ddH2O was 
performed. For the washing, at least 1 column volume (CV) was used in terms of water 
amount. Then, before starting the experiment, the column and whole system were 
equilibrated with gel filtration buffer whose volume should be at least 1.5 CV. For the 
injection of protein sample to AKTA pure, sample volume should be equal or lower than 
50 µl for Superdex 200 Increase 5/150 GL column; 500 µl for Superdex 200 Increase 
10/300 GL column. The protein was injected into the corresponding loop for each column 
type with a syringe and the experiment was initiated. When protein completed its passage 
from in front of a UV detector, it was collected in a 96-well collector plate. Depending 
on UV absorbance at 280 nm, the location of desired protein within the plate was found. 
When the samples from different peak positions of UV-absorbance graph were selected, 
they were loaded to SDS gel to perform SDS-PAGE for determination of our desired 
protein in the pure form and its boundaries of purity.  
 
 
3.2.5. Surface Plasmon Resonance 
 
For surface plasmon resonance (SPR) experiments, BIACORE T200 was applied. SPR is 
a technique used to identify protein-protein interactions quantitatively. Also, kinetic 
parameters of the interactions among these proteins can be studied with the help of SPR. 
The logic behind this technique is based on the changes in refractive indices when 
polarized light hits to a gold film. With the help of a prism, the light coming from a light 
source is focused on the gold film. The reflected light is collected with a detector. When 
there is a change in the mass attached to the gold surface, there will be a change in the 
refractive index of the medium at the interface as well. According to mass change on the 
surface of gold film, the refractive index differs proportionally and absorbance of some 
light part happens. All these events give information about the quantification of binding 
taking place on the surface. It is represented as a resonance unit (RU).  
 
In this method, ligand is known as the attached molecule on the gold surface. Analyte is 
known as the molecule found in the mobile phase that flows on the surface of the chip 
with the running buffer. pH scouting, ligand immobilization on the surface, ligand 
injection and surface generation are some of the basic steps in SPR. For this study, 
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PATZ1-BTB, PATZ2-BTB and MIZ1-BTB were immobilized covalently on the Sensor 
Chip CM5. CM-series sensor chips have a carboxymethylated dextran matrix attached to 
the gold surface. Ligand is covalently bound to sensor surface with amine coupling. To 
do immobilization, surface of the gold chip should initially be activated. Activation is 
performed in such a way that mixture of of 1-ethyl-3- (3- dimethylaminopropyl) 
carbodiimide (EDC) and N- hydroxysuccinimide (NHS) is passed on the surface and 
while being passed, they react with carboxyl groups of the dextran. Eventually, 
succinimide esters are formed on the surface. These reactive ester groups are able to 
interact with amino groups of the ligand and thus form covalent bonds between dextran 
surface and ligand. In order to result in successful reaction, electrostatic interactions 
among ligand and dextran should be strong. The dextran matrix has negative charge when 
pH is above 3.5. pH of immobilization buffer, which is acetate buffer, should be above 
3.5 and below the isoelectronic point of the ligand (it means that ligand should be 
positively charged and matrix should be positively charged) so that efficient electrostatic 
interactions of the ligand to the surface can be achieved. For determining the suitable pH 
of acetate buffer for coupling, pH scouting step was performed. Acetate buffers with 
different pH values, 4, 4.5, 5, 5.5, were used for pH scouting and the interaction among 
the surface and ligand was examined by checking differences in their RU values.  
 
After pH scouting was done, immobilization with chosen acetate buffer (pH 4 for MIZ1-
BTB, pH 5 for PATZ1 and pH 4 for PATZ2) was performed as a next step. Then, 
deactivation of unbound surface was carried out with the help of ethanolamine (pH 8.5). 
Different concentrations of analytes, MIZ1-BTB, PATZ1-BTB and PATZ2-BTB, passed 
on the surface separately. Dilutions for analytes were done with HBS-EP + running 
buffer. After this step, regeneration of the surface was performed to take away analyte 
bound to the ligand on the surface. This is one of the most crucial steps because it 
influences the binding activity of the surface for upcoming experiments and chip life-
time. In order to regenerate the surface, glycine pH 3 was used. Thanks to regeneration, 
chip is prepared for other experiments.  
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3.2.6. Fluorescent Two- Hybrid (F2H) Assay 
 
 
3.2.6.1. Vector Construction for pcDNA 3.1/ myc-His (-) B- TagGFP-BTB Domain 
and pcDNA 3.1/ myc-His (-) B-TagRFP-BTB Domain 
 
pcDNA 3.1/ myc-His (-) B is a vector used for construction of mammalian expression 
systems. It was selected for cloning due to the presence of NheI, XhoI and NotI cut sites 
in its multiple cloning site. Initially, TagGFP was taken from TagGFP-p53 plasmid via 
PCR amplification followed by PCR clean-up and NheI and XhoI digestion. TagRFP was 
obtained from TagRFP-MDM2 plasmids via its digestion with NheI and XhoI (TagGFP-
p53 and TagRFP-MDM2 plasmids were supplied from F2H Assay Chromotek). pcDNA 
3.1/ myc-His (-) B vector was also digested with these two enzymes to create compatible 
ends for ligation. These digestions were performed in thermocycler at 37°C for 2 hours. 
 
5X Q5 reaction buffer 5 µl 
10 mM dNTP 0.5 µl 
10 µM forward primer (CMV Forward) 1.25 µl 
10 µM reverse primer (TagGFP-XhoI&SmaI-Reverse) 1.25 µl 
Template DNA (1 ng) 1 µl 
Q5 HF DNA Polymerase 0.25 µl 
ddH2O To 25 µl 
 
 TagGFP TagRFP Vector 
DNA PCR Product 1 µg 2 µg 
CutSmart Buffer (NEB) 5 µl 5 µl 5 µl 
NheI-HF (20,000 U/ml) (NEB) 0.5 µl 0.5 µl 0.5 µl 
XhoI (20,000 U/ml) (NEB) 0.5 µl 0.5 µl 0.5 µl 
ddH2O To 50 µl To 50 µl To 50 µl 
 
After digestions, inserts were cleaned by NucleoSpin Gel and PCR Clean-up kit. Digested 
vector was dephosphorylated and then run on 1% agarose gel to separate digested DNA 
from undigested one. Digested part was gel extracted and purified by NucleoSpin Gel and 
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PCR Clean-up kit. Insert to vector molar ratio was adjusted to 3:1 for each cloning and 
ligation was performed according to this setting. Transformation of ligation mixture into 
DH5α competent cells was followed and single colonies were taken for isolation of their 
plasmid DNA. These plasmids were controlled via diagnostic digestion with suitable 
enzymes and their corresponding conditions and buffers. Positive colonies were selected 
and sent for sequencing. 
 
When pcDNA 3.1/ myc-His (-) B- TagGFP and pcDNA 3.1/ myc-His (-) B- TagRFP 
constructs were obtained, next step was the addition of selected BTB domains to the ends 
of these tags. This step was performed differently for each construct. For pcDNA 3.1/ 
myc-His (-) B- TagGFP, BTB domains were initially PCR amplified by using their 
corresponding forward primers with XhoI and reverse primers with NotI cut sites. Then, 
PCR products were cleaned up by NucleoSpin Gel and PCR Clean-up kit. Inserts and 
vectors were digested with XhoI and NotI enzymes for 2 hours at 37°C. 
 
5X Q5 reaction buffer 5 µl 
10 mM dNTP 0.5 µl 
10 µM forward primer (XhoI-BTB Domain) 1.25 µl 
10 µM reverse primer (BTB Domain-NotI) 1.25 µl 
Template DNA (1 ng) 1 µl 
Q5 HF DNA Polymerase 0.25 µl 
ddH2O To 25 µl 
 
 BTB Domain Vector 
DNA PCR Product 2 µg 
CutSmart Buffer (NEB) 5 µl 5 µl 
Not-HF (20,000 U/ml) (NEB) 1 µl 1 µl 
XhoI (20,000 U/ml) (NEB) 1 µl 1 µl 
ddH2O To 50 µl To 50 µl 
 
After digestion, inserts were PCR cleaned-up, vector was dephosphorylated, run on the 
gel to obtain only the digested part and purified. The molar concentration ratio of insert 
to vector (3:1) was calculated for each insert and vector and ligation reaction was set up 
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accordingly. After ligation; transformation, picking of colonies for plasmid DNA 
isolation, diagnostic digestion and sequencing steps were performed in the given order. 
For pcDNA 3.1/ myc-His (-) B- TagRFP, BTB domains were taken from pET-47b (+)-
BTB Domain constructs by digestion of them with SmaI and NotI enzymes. Meanwhile, 
pcDNA 3.1/ myc-His (-) B- TagRFP vector was digested with XhoI enzyme for 2 hours 
at 37°C first, then it was treated with Klenow fragment for 15 minutes at 37°C. In order 
to stop the reaction, heating at 65°C for 15 minutes was performed. This treatment was 
carried out to blunt the 5’ overhang created after XhoI digestion. By blunting, 5’ end was 
aimed to make compatible with the 5’ end of BTB domain insert created by SmaI 
digestion.  
 
 pcDNA 3.1/ myc-His (-) B- TagRFP 
DNA 5 µg 
10X Buffer R (Fermentas) 3 µl 
XhoI (Fermentas) 1 µl 
ddH2O To 30 µl 
 
 pcDNA 3.1/ myc-His (-) B- TagRFP 
Linear DNA 30 µl 
10X Reaction Buffer for Klenow 5 µl 
10 mM dNTP 1.25 µl 
Klenow fragment (Fermentas) 1 µl 
ddH2O To 50 µl 
 
After Klenow fragment treatment, vector was digested with NotI enzyme. After SmaI and 
NotI digestions, the inserts were cleaned up. The digested vector was run on the gel, 
double digested part of it was extracted and purified. 3:1 molar concentration ratio of 
insert to vector was calculated and according to this calculation, ligation mixture was 
prepared. After ligation; transformation, colony selection, plasmid DNA isolation, 
diagnostic digestion and sequencing parts were carried out respectively.  
 
 
 
55 
 
3.2.6.2. PEI Transfection of F2H Assay Plasmids 
 
The day before transfection, BHK cells were seeded in 6 well plate in such a way that 
each well should have 150,000 cells. For transfection, 10 µl PEI was used for all 
conditions. Combinations of plasmids used and their amounts are shown in Table 3.4.  
 
Table 3. 5 Combination of plasmids and their amounts 
 GBP-
LacI 
TagGFP-
BTB 
TagRFP-
BTB 
TagGFP TagRFP BFP-
NCOR 
BFP-
SMRT 
BFP-
Only 
#1 500 
ng 
500 ng 1000 ng - - - - - 
#2 1000 
ng 
1000 ng - - - - - - 
#3 1000 
ng 
- 1000 ng - - - - - 
#4 500 
ng 
- 1000 
ng 
500 ng - - - - 
#5 500 
ng 
500 ng - - - 1000 ng - - 
#6 500 
ng 
500 ng - - - - 1000 ng - 
#7 500 
ng 
500 ng - - - - - 1000 
ng 
#8 500 
ng 
- - 500 ng - 1000 ng - - 
#9 500 
ng 
- - 500 ng - - 1000 ng - 
#10 500 
ng 
- - 500 ng - - - 1000 
ng 
#11 
 
500 
ng 
500 ng 500 ng - - 500 ng - - 
#12 
 
500 
ng 
500 ng 500 ng - - - 500 ng - 
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#13 1000 
ng 
- - - - 1000 ng - - 
#14 1000 
ng 
- - - - - 1000 ng - 
#15 - 1000 ng - - - 1000 ng - - 
#16 - 1000 ng - - - - 1000 ng - 
#17 - - 1000 ng - - 1000 ng - - 
#18 - - 1000 ng - - - 1000 ng - 
#19 - 500 ng 750 ng - - - - 750 
ng 
#20 500 
ng 
- 750 ng - - 750 ng - - 
#21 500 
ng 
- 750 ng - - - 750 ng - 
#22 2000 
ng 
- - - - - - - 
 
 
3.2.6.3. Live Cell Imaging 
 
After 24 hours from transfection, BHK cells were examined with live cell imaging 
microscope (ZEISS Axio Observer Z1) and their photographs were taken. 
 
57 
 
 
 
 
 
4. RESULTS 
 
 
 
4.1. Protein Purification of FAZF-BTB, MIZ1-BTB, PATZ1-BTB and PATZ2-
BTB domains  
 
 
In this study, we aimed to develop an assay for screening the interactions between various 
BTB domain transcription factors and systematically analyze the networks of these 
interactions with the help of this assay. Because BTB domains are the responsible unit of 
the interactions between these proteins, only this part of the whole protein was used 
during all experimental procedures. Previous studies have shown the presence of many 
BTB homodimers but only the limited numbers of heterodimers. To obtain a better 
representation of how BTB domains interact, a robust interaction matrix is required. Thus, 
we first analyzed in vitro interactions between BTB domains using surface plasmon 
resonance. In this experiment, His-tagged BTB-domains were attached to the surface of 
a CM5 chip and other His-tagged BTB-domains were passed over this chip. With this 
experimental set-up, we were able to examine the homodimerization and 
heterodimerization partners of selected BTB domains. The selected BTB domains and 
their estimated molecular weights for SPR are shown in Table 4.1. 
 
Table 4. 1 Estimated molecular weights of selected BTB domains in this part of the 
study 
BTB Domain Molecular Weight (kDa) for monomers 
FAZF-BTB 14.86 
MIZ1-BTB 14.97 
PATZ1-BTB 19.20 
PATZ2-BTB 17.07 
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To begin with, we constructed four bacterial expression plasmids which were expected 
to express His-tagged FAZF-BTB, MIZ1-BTB, PATZ1-BTB and PATZ2-BTB domains. 
Sequences of FAZF-BTB, MIZ1-BTB, PATZ1-BTB and PATZ2-BTB domains were 
PCR-amplified from cDNA of WT HCT116 colon cancer cell lines. These amplifications 
were performed by using a forward primer with a SmaI cut site and reverse primer with 
a NotI cut site. SmaI and NotI digested PCR products were cloned into a pET-47B (+) 
vector backbone digested with the same enzymes as well (Figure 4.1). 
 
  
Figure 4. 1 Construction of bacterial expression plasmids for selected BTB domains  
Sequences of FAZF-BTB, MIZ1-BTB, PATZ1-BTB and PATZ2-BTB domains were 
amplified by using the corresponding primers which were provided with suitable SmaI 
and NotI restriction enzyme cut sites. There were stop codons after each BTB domain 
sequence. The digested PCR products were cloned into the SmaI-NotI digested pET-47b 
(+) plasmid which is the bacterial expression vector. 
 
Next, we transformed pET-47b (+)-FAZF-BTB, pET-47b (+)-MIZ1-BTB, pET-47b (+)-
PATZ1-BTB and pET-47b (+)-PATZ2-BTB constructs into the Rosetta2 DE3 pLysS E. 
coli expression strain. This strain was chosen to express our eukaryotic proteins expressed 
from pET plasmids with the help of a chloramphenicol-resistant plasmid from which 
tRNAs for rare codons are expressed. The designed pET47b (+) plasmids expressed BTB 
domain proteins with an N-terminal His-tag used for purification by affinity 
chromatography. In these plasmids, protein expression from the T7 promoter is inhibited 
due to the expression of the LacI protein which is expressed from the same plasmid. This 
protein binds to Lac operator sites situated next to the T7 promoter and blocks the activity 
of this promoter by preventing the binding of T7 RNA polymerase to it. When cells are 
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treated with IPTG, an inducer that binds to LacI and prevents its binding to the Lac 
operator site, releasing LacI mediated repression. In the absence of LacI/Lac operator 
binding, T7 RNA polymerase can associate with the T7 promoter to initiate transcription. 
 
Before starting with large scale protein production, we performed a colony screening 
assay by picking random colonies after transformation and checked their protein 
expression capabilities in a small-scale. Induction of expression was performed by the 
addition of 0.1 mM IPTG to each culture. The results of all colony screening trials were 
positive (Figure 4.2) and confirmed that the BTB domain expression constructs in fact 
were capable of expressing these proteins in E.coli.  
 
For the large-scale protein production and purification, we continued with one of the 
positive colonies. For PATZ1-BTB, we used a construct in the same bacterial strain that 
was previously shown to express, thus we directly purified it in a large scale. We prepared 
1 L LB medium with corresponding antibiotics to culture the transformed bacteria. This 
culturing was carried out at 37°C (221rpm) until optical density at 600 nm reached to a 
value between 0.4 and 0.6. Then, we added 0.1 mM IPTG to each culture and put the 
cultures to shaker incubator overnight at 18°C for IPTG induction. The next day, we 
carried out affinity chromatography purification to obtain purified His-tagged BTB 
domains (see section 3.2.6.3.) and visualized our samples by SDS-PAGE. The expected 
molecular weights of FAZF-BTB, MIZ1-BTB, PATZ1-BTB and PATZ2-BTB were 
14.86, 14.97, 19.20 and 17.07 kDa respectively and we obtained these values (except for 
MIZ1-BTB) at 100 mM imidazole (IZ) elution (except for PATZ1-BTB). The band we 
got at 100 mM IZ elution for MIZ1-BTB was lower than expected in terms of molecular 
weight and PATZ1-BTB domain band was obtained at 300 mM IZ elution. Moreover, the 
eluted BTB domains contained contaminant proteins, which were larger than our BTB 
domains (Figure 4.3). Furthermore, bands for same proteins were seen in fractions of 
sonicated lysate, non-retained (NR) and pellet samples. This means that our proteins were 
not 100% soluble because the parts in the pellet shows the insoluble fractions. Obtaining 
proteins in the NR fraction was not desired because it shows that we were not able to 
collect all the expressed proteins to completion.  
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Next, we concentrated our proteins with the help of a concentrator that has 10 kDa 
molecular weight cutoff (MWCO) to a volume of approximately 1 ml. This was necessary 
to load our samples to the AKTA pure size exclusion chromatography purification and 
also for removing the contaminant proteins. The final concentrations of our samples were 
8.15 mg/ml for FAZF-BTB, 12.64 mg/ml for MIZ1-BTB, 6.67 mg/ml for PATZ2-BTB 
and 20 mg/ml for PATZ1-BTB.  
 
Figure 4. 2 Colony screening for FAZF-BTB, PATZ2-BTB and MIZ1 BTB domains 
FAZF-BTB (on the top-left), PATZ2-BTB (on the top-right) and MIZ1-BTB (at the 
bottom) domains were expressed in Rosetta2 DE3 pLysS in a small scale. 14% SDS gel 
was used for SDS-PAGE and expected sizes of proteins are around 14.86, 17.07 and 14.97 
kDa respectively. 
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Figure 4. 3 Affinity purification of His-tagged FAZF-BTB, MIZ1 BTB, PATZ1-BTB 
and PATZ2-BTB domains 
 
FAZF-BTB (on the top-left), MIZ1-BTB (on the top-right) and PATZ2-BTB (at the 
bottom-left) and PATZ1-BTB (at the bottom-right) domains were purified with affinity 
purification by using HisPur Cobalt Superflow Agarose resin (Thermo Fisher Scientific). 
The collected samples from each step were visualized by 14% SDS-PAGE and expected 
sizes of proteins are around 14.86, 14.97, 19.20 and 17.07 kDa respectively. 
 
As a next step, we performed size exclusion chromatography (SEC) according to the 
guidelines in section 3.2.6.6. Before sample injection, we calibrated the column 
(Superdex 200 Increase 5/150 GL) used for the FAZF-BTB domain sample because it 
required calibration before use. For this purpose, low molecular weight (LMW) kit was 
used and a calibration curve was calculated (Figure 4.5). For MIZ1-BTB and PATZ2-
BTB domains, Superdex 200 Increase 10/300 GL column was used, which was already 
calibrated. For the PATZ1-BTB domain, a HiLoad16/60-SD75 column was used and no 
calibration was performed for this already-calibrated column. After SEC was completed, 
we collected the purified protein from the peaks measured by absorbance at 280 nm for 
MIZ1-BTB, PATZ1-BTB and PATZ2-BTB (Figure 4.4.A, B, C and D). For FAZF-BTB, 
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we only checked the accuracy of molecular weight of the dimer from the graph we 
obtained. The expected molecular weight of FAZF-BTB homodimer was 29.72 kDa. 
When we examined the graph (Figure 4.5.A), we could see that the peak at 280 nm 
absorbance was obtained when the retention volume was 2.02, which corresponds to the 
MW around 30 kDA according to the calibration curve (Figure 4.4). This means that 
theoretically calculated MW of FAZF-BTB dimer shows high concordance with the 
experimental value. Moreover, there was another peak whose retention volume was 3.03 
ml most likely due to the presence of imidazole in the sample. Literature review 
confirmed that this peak arises to the absorbance properties of the ring structure of 
imidazole. 
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Figure 4. 4 Size exclusion chromatography result of FAZF-BTB, MIZ1-BTB, 
PATZ2-BTB and PATZ1-BTB domains 
We carried out size exclusion chromatography by the use of AKTA Pure for removal of 
contaminant proteins. The blue graph exhibited absorbance at 280 nm which represents 
the presence of proteins. On the other hand, purple graph showed absorbance at 254 nm 
which represents the presence of DNA contamination. (A) The graph showed the curve 
of absorbance (mAU) versus elution volume (ml) of His-tagged FAZF-BTB domain. The 
peak at elution volume of 2.02 ml was the point where His-tagged FAZF-BTB domain 
was expected to come. (B), (C) and (D) On the left sides, absorbance versus elution 
volume graphs of His-tagged MIZ1-BTB (part B), PATZ2-BTB (part C) and PATZ1-
BTB (part D) domains were available. The elution fractions around the peak of each 
protein were collected and visualized with SDS-PAGE to analyze their purities. Expected 
sizes of His-tagged MIZ1-BTB, PATZ2-BTB and PATZ1-BTB are around 14.97, 17.07 
and 19.20 kDa respectively. Obtained results were compatible with these expected values. 
Input was the initial sample taken before the injection.   
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Figure 4. 5 Standard curve for low molecular weight proteins 
For the calibration of Superdex 200 Increase 5/150 GL column, low molecular weight 
(LMW) kit was used. It contains five proteins with their molecular weights ranging from 
6.5 kDa to 75 kDa. The retention volume of the peak of FAZF-BTB was 2.02 ml. This 
value approximately corresponds to the MW between 30 and 33 kDa.    
 
For His-tagged MIZ1-BTB, PATZ2-BTB and PATZ1-BTB, we collected samples from 
elution fractions. E2, E4, E8 and E10 were the samples for MIZ1-BTB. E2, E4 and E8 
were the samples for PATZ2-BTB. B9, C5, C11, D1, D3, D5, D7 and D9 were the 
collected samples for PATZ1-BTB. We selected these fractions around the peaks 
obtained in order to understand the boundaries of pure proteins. Then, we analyzed them 
with SDS-PAGE and we ended up with the fact that for MIZ1-BTB, desired protein was 
found between E2 and E8 fractions; for PATZ2-BTB, it was available between E2 and 
E7; for PATZ1-BTB it was found between C11 and D9. After this decision, from E2 to 
E8 for MIZ1-BTB; from E2 to E7 for PATZ2-BTB and from C11 to D9 for PATZ1-BTB 
were pooled and their concentrations were measured individually. They were 1.95 mg/ml, 
1.50 mg/ml and 1.67 mg/ml respectively. The final versions of the samples were flash-
frozen in liquid nitrogen. In conclusion, the SEC step is important to remove most 
impurities that were present after affinity chromatography. These double purified samples 
were used in SPR experiments. 
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4.2. Screening the interactions of MIZ1-BTB, PATZ1-BTB and PATZ2-BTB 
domains in vitro by surface plasmon resonance (SPR) 
 
 
We used the surface plasmon resonance assay to determine the interaction affinities of 
selected purified BTB domains and their capability for homodimerization, 
heterodimerization, homotetramerization and heterotetramerization by the use of Biacore 
T200 machine. The first step of this experiment was pH scouting to find an appropriate 
surface immobilization pH for BTB domains. For this purpose, ligands were diluted in 
sodium acetate buffers with different pH values (pH 4, pH 4.5, pH 5 and pH 5.5) to reach 
a final concentration of 20 µg/ml for each sample. The contact time was 120 seconds and 
the flow rate was 30 µl/ min. The response unit (RU) corresponds to the change in 
refractive index. The binding to the surface was plotted in terms of function of time. In 
order to select the best pH, we identified the pH at which the highest signal was obtained 
and where the signal returned to baseline completely. In the light of this information, we 
chose the pH 4 for MIZ1-BTB, pH 5 for PATZ1-BTB and pH 4 for PATZ2-BTB as 
immobilization pH (Figure 4.6). pH of immobilization buffer should be higher than 3.5 
and lower than isoelectronic point (pI) of ligands to achieve efficient immobilization to 
the surface. For MIZ1-BTB, PATZ1-BTB and PATZ2-BTB pI values are 5.87, 5.89 and 
5.29 respectively. Therefore, we met all the requirements for immobilization step.  
 
   
-4000
-2000
0
2000
4000
6000
8000
10000
12000
-50 0 50 100 150 200 250 300 350
20 µg/ml MIZ1-BTBRU
R
e
s
p
o
n
s
e
 (
0
 =
 b
a
s
e
li
n
e
)
sTim e (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5
10 mM Acetate 5.5
-4000
1000
6000
11000
16000
-50 0 50 100 150 200 250 300 350
20 µg/ml PATZ1-BTBRU
R
e
s
p
o
n
s
e
 (
0
 =
 b
a
s
e
li
n
e
)
sTim e (0 = baseline)
10 mM Acetate 4
10 mM Acetate 4.5
10 mM Acetate 5
10 mM Acetate 5.5
66 
 
 
Figure 4. 6 pH scouting experiment for MIZ1-BTB, PATZ1-BTB and PATZ2-BTB 
20 µg/ml sample was used for each experiment. pH 4, pH 5 and pH 4 were chosen as 
immobilization pH respectively.  
 
As a next step, we performed immobilization of ligands to the surface of the CM5 chip. 
We used the same contact time and flow rate and also the corresponding pH values for 
each sample. Instead of 20 µg/ml protein samples, we decided to use 10 µg/ml and arrange 
our concentrations by diluting the samples with suitable buffers. We aimed to immobilize 
80 RU of protein onto the surface of the chip. We performed the necessary steps according 
to section 3.2.5. Finally, we immobilized 77.2 RU of MIZ1-BTB, 66.5 RU of PATZ1-
BTB and 86.0 RU of PATZ2-BTB ligands. The results for pH scouting and 
immobilization are shown in Table 4.2. 
 
Table 4. 2 Overall information and immobilization results related to selected BTB 
domains 
 
After immobilization of selected His-tagged BTB domain protein ligands to the CM5 
chip, we carried out a tetramerization test for these proteins. As an analyte, we used 
MIZ1-BTB, PATZ1-BTB and PATZ2-BTB domains. These three BTB domains were 
separately passed over the CM5 chip which had been bound by MIZ1-BTB, PATZ1-BTB 
and PATZ2-BTB domains. For each analyte, we used 7 different concentrations; 0, 
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15.625 nM, 62.5 nM, 250 nM, 500 nM, 1000 nM and 2000 nM. For all dilutions to get 
correct concentrations, we used the running buffer, HBS- EP +. 
 
The results were analyzed based on the binding using multiple cycle kinetics (according 
to the 1:1 binding model) which are shown in Table 4.3, 4.4 and 4.5 and visualized in 
Figure 4.7. In the table, the U value was also available. This is a parameter which 
represents the uniqueness of the Rmax value (represents analyte binding capacity 
theoretically calculated by (Analyte MW/Ligand MW) x RL x Sm in which RL is the 
immobilized ligand and Sm is the stoichiometric ratio). When the U value is small, the 
confidence in the results becomes greater. A U value, higher than 25, indicates that the 
calculated kinetic constant is inaccurate. According to these preliminary experiments, it 
is possible that MIZ1-BTB and PATZ1-BTB can homo-tetramerize. Also, there was a 
possible interaction between MIZ1-BTB and PATZ1-BTB which may be interpreted as 
the presence of MIZ1-PATZ1 heterodimers or homodimers. These interactions were 
concentration-dependent; the higher the concentration the better the binding we got at the 
end. We did not observe any interaction between PATZ1 and PATZ2 dimers or PATZ2 
and MIZ1 dimers. Unfortunately, the SPR results were not as clean as expected, most 
likely due to the impurities and imidazole in our protein samples. Normally the SPR curve 
should be above the baseline while in our experiments the application of analyte resulted 
in a dip of the RU values, most likely due to solvent and impurity effects. 
 
Table 4. 3 The obtained results for MIZ1-BTB ligand; MIZ1-BTB, PATZ1-BTB and 
PATZ2-BTB analytes 
 
Table 4. 4 The obtained results for PATZ1-BTB ligand; MIZ1-BTB, PATZ1-BTB 
and PATZ2-BTB analytes 
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Table 4. 5 The obtained results for PATZ2-BTB ligand; MIZ1-BTB, PATZ1-BTB 
and PATZ2-BTB analytes 
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Figure 4. 7 Binding assay for MIZ1-BTB, PATZ1-BTB and PATZ2-BTB 
After activation and immobilization of His-tagged MIZ1-BTB, PATZ1-BTB and 
PATZ2-BTB domains, different concentrations of analytes (His-tagged MIZ1-BTB, 
PATZ1-BTB and PATZ2-BTB domains) were passed over the chip. In the right part of 
each graph, the concentrations used, 0, 15.625 nM, 62.5 nM, 250 nM, 500 nM, 1000 nM 
and 2000 nM, were found. The ones that did not follow the regular fashion were excluded 
from the graphs. 
 
 
4.3. Fluorescent two-hybrid assay for assessing the rules of dimerization of BTB 
domains with each other and with NCOR/SMRT corepressors 
 
 
Fluorescent two-hybrid (F2H) assay is a technique used to investigate protein-protein 
interactions by the use of fluorescent live-cell microscopy. This system is based on 
tethering strategy which is applied by the use of lac operator sequence. The lac operator 
sequences are repeatedly and randomly integrated into the genome of baby hamster 
kidney (BHK) cells. In this system, we tagged our selected BTB domains with green 
(TagGFP) and red (TagRFP) fluorescent proteins separately and transfected them into 
these BHK cells together with green fluorescent binding protein (GFP nanobody)-LacI 
construct (Figure 4.8). Green fluorescence tagged BTB domains have the potential to be 
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localized on the lac operator site by the use of GBP-LacI construct because the LacI part 
can bind to this operator site and GBP part can recruit GFP-tagged BTB domains by 
binding to their GFP sides. Eventually, green focus formation occurs in the nucleus. Red 
fluorescent-tagged BTB domains have the potential to bind to the GFP-tagged BTB 
domains from BTB sides and red focus formation takes place. Eventually, colocalization 
of these two colors happens and it gives the information about the presence of interaction 
or dimerization among those BTB domains (91). We also checked the interactions of 
NCOR and SMRT corepressors which were tagged with blue fluorescent protein (BFP) 
with BTB dimers by using the same system (Figure 4.9). The selected BTB domains for 
this experimental set up were BACH1-BTB, BACH2-BTB, BCL6-BTB, FAZF-BTB, 
KAISO-BTB, LRF-BTB, MIZ1-BTB, PATZ1-BTB, PATZ2-BTB, PLZF-BTB and 
ZBTB4-BTB. BFP-SMRT and BFP-NCOR constructs were already available so that we 
directly used them for transfection.  
 
Initially, we seeded BHK cells on the 10 cm culture dish and co-transfected our plasmids 
in different combinations to check the functionality of the system (see Table 3.4). Among 
all transfection combination candidates, we chose BCL6-BTB as our positive control 
because it has been known that BTB domain of BCL6 must homodimerize for correct 
folding of the final functional protein and upon this obligate dimerization, the recruitment 
of corepressor proteins such as NCOR, SMRT and BCOR takes place, which eventually 
represses target genes (95). In other words, all the possible interactions should be seen in 
BCL6-BTB transfection combinations that we aimed to perform and we saw all of them 
as we expected (Figure 4.9).  
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Figure 4. 8 Constructed plasmids for F2H assay and their transfection method  
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Figure 4. 9 Experimental approach of fluorescent two-hybrid (F2H) assay for this 
study and positive controls 
In the first picture, we see that there are lac operator sites integrated into the genome of 
BHK cells and GBP-LacI fusion protein binds to these regions. When there is an 
interaction chain between GBP and TagGFP proteins and also BTBs of TagGFP fused 
and TagRFP fused proteins, the formation of green and red foci in the nucleus should be 
the result. In the second picture, we saw the result of the same experiment for TagGFP-
BCL6-BTB and TagRFP-BCL6 constructs. In the third picture, in addition to same 
experimental set-up, BFP-NCOR and BFP-BCOR fused proteins are added to check their 
interactions with BTB dimers. The experimental results for this design could be seen in 
picture 4 and 5 for TagGFP-BCL6-BTB and TagRFP-BCL6 constructs. 
 
To verify this designed system, we performed the transfection of different combinations 
of the F2H plasmids which were considered as positive controls for this study. When we 
transfected the TagRFP-BCL6-BTB and TagGFP-BCL6-BTB plasmids, there was no 
focus formation because of absence of GBP-LacI fusion protein in the system. Secondly, 
we performed transfection of TagRFP-BCL6-BTB and GBP-LacI plasmids and again we 
did not see any focus formation due to absence of GFP protein. Thirdly, we carried out 
transfection of TagGFP-BCL6-BTB and GBP-LacI fusion protein and eventually we 
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observed green focus formation only. This shows that GBP-LacI fusion protein is 
responsible for localization of TagGFP-BCL6-BTB on the lac operator sites in the 
nucleus. Finally, we transfected all three plasmids together and obtained both green and 
red foci at the same place in the nucleus (Figure 4.10) 
 
 
 
 
 
Figure 4. 10 F2H assay verification 
TagGFP-BCL6-BTB, TagRFP-BCL6-BTB and GBP-LacI-GBP plasmids were 
transfected to BHK cells with different combinations. Red and green foci were only 
formed at the same place when all three plasmids were transfected together. Overall, 
system worked as in the expected way. 
 
In the second part of the experiment, we checked availability of homodimerization among 
the other selected BTB domains. For this purpose, all three plasmids for each BTB 
domain were transfected into BHK cells. According to the observations we made after 
transfection, we could say that BACH2 BTB, KAISO-BTB, LRF-BTB, MIZ1-BTB, 
PATZ1-BTB, PATZ2-BTB and PLZF-BTB domains homodimerized and gave the same 
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result which was obtained for BCL6-BTB, our positive control. On the contrary, we did 
not get the same results for BACH1-BTB domain; it only formed green foci within the 
context of this experimental set-up (Figure 4.11). The quantifications of all these 
dimerizations that we observed are seen in Figure 4.12.  
 
   
   
   
   
Figure 4. 11 Homodimerization patterns for selected BTB domains 
75 
 
All three plasmids with corresponding BTB domains were transfected into BHK cells and 
their homodimerization statuses were visualized. Except BACH1-BTB; BACH2-, 
KAISO-, LRF-, MIZ1-, PATZ1-, PATZ2- and PLZF-BTB domains could homodimerize 
and colocalization of green and red foci are the sign of this homodimerization. 
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Figure 4. 12 The pie charts for the colocalization of green and red foci in the 
homodimerizations of selected BTB domains 
The percentages of green and red foci colocalization among all green foci for each 
homodimerization experiment are represented as in the form of pie charts above. The gray 
slices correspond to the colocalization of green and red foci, whereas white slices 
represent the green foci only. n is the number of cells having all green foci observed after 
corresponding transfections.  
 
In the third part of the experiment, we checked the availability of heterodimerization for 
selected BTB domains. For this purpose, we performed several transfection experiments 
in different combinations (see Table 3.4). Among all candidates (Figure 4.15), only 
PATZ1-BTB and PATZ2-BTB could heterodimerize (Figure 4.13). The quantifications 
for this heterodimerization are shown in Figure 4.14.  
 
    
Figure 4. 13 Heterodimerization experiment for PATZ1-BTB and PATZ2-BTB 
domains 
Among all combinations we tried, only PATZ1-BTB and PATZ2-BTB were able to 
heterodimerize in both conditions, TagGFP-PATZ1-BTB & TagRFP-PATZ2-BTB; 
TagGFP-PATZ2-BTB & TagRFP-PATZ1-BTB. This heterodimerization was inferred 
from the colocalization of green and red foci. 
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Figure 4. 14 The pie charts for the colocalization of green and red foci in the 
heterodimerizations of PATZ1 and PATZ2 BTB domains 
 
The percentages of green and red foci colocalization among all green foci for PATZ1 and 
PATZ2 BTB heterodimerization are represented as in the form of pie charts above. The 
gray slices correspond to the colocalization of green and red foci, whereas white slices 
represent the green foci only. n is the number of cells having all green foci observed after 
corresponding transfections.  
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Figure 4. 15 Heterodimerization experiment for selected BTB domains 
Except PATZ1-BTB and PATZ2-BTB combinations, we did not observe any other 
interactions and thus heterodimerization of selected BTB domains because only green 
foci were visible and there was no colocalization of green foci and red foci in these 
partners. 
 
The overall interaction matrix which we obtained after these experiments is seen in Figure 
4.16. According to this matrix, we can say that heterodimerization might not take place 
between the selected BTB domain partners seen in the matrix; only exception was 
PATZ1-BTB and PATZ2-BTB in our study.  
 
 
Figure 4. 16 An interaction matrix for the selected BTB-domains 
 
In the last part of this study, we wanted to check the availability of interactions of BTB 
dimers with NCOR and SMRT corepressor proteins. For this purpose, we started with 
BCL6-BTB domain to analyze its behaviors within the context of different transfection 
combinations. When TagGFP-BCL6, TagRFP-BCL6, BFP-SMRT/NCOR and GBP-LacI 
plasmids were all transfected into BHK cells, we saw the formations of green, red and 
blue foci at the same spots. As a next step, we performed transfection of TagGFP-BCL6, 
BFP-SMRT/NCOR and GBP-LacI plasmids into the cells and examined the results under 
the live-cell imaging microscope. Again, we saw colocalization of green and blue foci 
within the nucleus. In the first case, the dimerization of BCL6-BTBs happened between 
TagGFP and TagRFP tagged versions. In the second case, TagGFP tagged BTB domains 
homodimerized in themselves. In both cases, we can say that there might be some 
interactions between BCL6-BTB dimers and NCOR/SMRT corepressors. Then, we 
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carried out another transfection in which TagGFP-BCL6, BFP-Only and GBP-LacI 
plasmids were available and we saw that there was only green focus formation; no blue 
foci were available. This might be an indication of the necessity of NCOR/SMRT 
peptides for the interaction to occur. Next, we transfected TagGFP-BCL6, BFP-
NCOR/SMRT plasmids only and obtained no focus formations, which means that for the 
green focus to appear, the presence of GBP-LacI is necessary and without green foci 
formation, blue foci cannot be formed as well due to the absence of the interactions 
between BCL6-BTB dimers. Furthermore, we carried out the transfections of TagRFP-
BCL6, BFP-SMRT/NCOR and GBP-LacI plasmids; and TagRFP-BCL6, BFP-
SMRT/NCOR separately. Still, we did not get any focus formation in both conditions due 
to absence of TagGFP-BCL6 and GBP-LacI constructs which are crucial for green focus 
formation. Moreover, we did TagGFP-BCL6, TagRFP-BCL6 and BFP-SMRT/NCOR; 
TagGFP-BCL6, TagRFP-BCL6 and BFP-Only transfections and we did not obtain any 
focus formation (Figure 4.17).  The quantifications of positive data for these experiments 
are shown in Figure 4.18. 
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Figure 4. 17 The interaction table for BCL-BTB dimers and BFP-NCOR/BFP-
SMRT and BFP-Only proteins 
From A to E and H to I, the transfection conditions contained GBP-LacI fusion protein 
as well. From F to G and J to M, there was no addition of GBP-LacI into the transfection 
conditions. 
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Figure 4. 18 The pie charts for the colocalization of green, blue and red foci for 
interactions between TagGFP-BCL6-TagRFP-BCL6 dimers and NCOR/SMRT 
corepressors; and the colocalization of green and blue foci for interactions between 
TagGFP-BCL6 dimers and NCOR/SMRT corepressors 
 
The gray slices correspond to the colocalization of green blue/red foci, whereas white 
slices represent the green foci only. n is the number of cells having all green foci observed 
after corresponding transfections.  
 
According to the conducted studies, we know that BCL6-BTB dimers interacts with 
NCOR and SMRT corepressors (95) and our F2H systems confirmed this information. 
As a next step, we wanted to check whether these interactions are also valid for PATZ1-
BTB dimers. For this purpose, we carried out three different transfection combinations. 
In the first scenario, we transfected TagGFP-PATZ1-BTB, BFP-NCOR and GBP-LacI 
plasmids. In the second scenario, we performed TagGFP-PATZ1-BTB, BFP-SMRT and 
GBP-LacI plasmids. Finally, TagGFP-PATZ1-BTB, BFP-Only and GBP-LacI were 
transfected into the BHK cells. For the first two cases, we saw that both green and blue 
foci were visible at the same spots which might be interpreted as colocalization. However, 
blue foci were too faint comparing with the green foci (Figure 4.19). As a result of third 
case, we observed that only green focus formation was available. No blue foci were seen 
in the areas where green foci were localized (Figure 4.21), which might be interpreted as 
the presence of NCOR/SMRT peptides are required for interactions to take place.  
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Figure 4. 19 F2H assay to check the availability of interaction between PATZ1-
BTB dimers and NCOR/SMRT corepressor 
Our preliminary data show that there might be an interaction between PATZ1-BTB 
dimers and NCOR/SMRT corepressor proteins. 
 
The quantification of these data is represented in Figure 4.20.  
 
  
 
Figure 4. 20 The pie charts for the colocalization of green and blue foci in 
interactions between PATZ1 homodimers and NCOR/SMRT corepressors 
The percentages of green and blue foci colocalization among all green foci for interactions 
between PATZ1 homodimers and NCOR/SMRT corepressors are represented as in the 
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form of pie charts above. The gray slices correspond to the colocalization of green and 
blue foci, whereas white slices represent the green foci only. n is the number of cells 
having all green foci observed after corresponding transfections.  
 
 
Figure 4. 21 F2H assay to check the necessity of NCOR/SMRT proteins for 
interaction.  
Our preliminary data show that there was no interaction in the absence of NCOR/SMRT 
peptide. 
 
 
The overall results for positive interactions are clarified in terms of numbers in Table 4.6.  
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Table 4. 6 The quantification table for all positive interactions  
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5. DISCUSSION 
 
 
 
The broad complex, tramtrack, bric-a-brac, and zinc finger (BTB-ZF) proteins are a 
family of transcriptional factors which are evolutionarily well-conserved. There are 49 
known members of this family encoded in human genome and these members have 
common characteristics such as the presence of one or more C-terminal C2H2 Krüppel-
type zinc finger DNA binding domain and an N-terminal BTB/POZ domain responsible 
for the mediation of protein-protein interactions. These transcriptional factors regulate 
the expression pattern of target genes generally in a repressive way by binding to the 
regulatory regions in target genes through their ZF domain in a sequence specific manner. 
This binding is coupled with the recruitment of corepressor proteins which have roles in 
the chromatin remodeling and transcriptional silencing/activation depending on the 
cellular context. The formation of cofactor complexes is mainly achieved by the BTB 
domain that is able to interact directly with the corepressors and histone modifying 
enzymes such as SMRT, NCOR, BCOR, Sin3A and HDAC. Furthermore, this domain 
mediates the homodimerization and heterodimerization between different members of the 
family. One ZBTB family protein, BCL6 is a good example: BCL6 is able to 
homodimerize in the proper cellular conditions. Also, it can heterodimerize with other 
BTB-ZF proteins such as PLZF, LRF and MIZ1 (26). The members of this family is 
responsible for the regulation of normal and proper development of lymphocytes, fertility, 
skeletal morphogenesis, embryonic and neurological development (21). Apart from these 
BTB-ZF transcription factors, we studied two other proteins, BACH1 and BACH2 which 
are members of both BTB and CNC homology and the Cap‘n’Collar type of the basic 
region-leucine zipper factor family. They are able to form heterodimers with small MAF 
proteins and this heterodimerization results in the repression of target gene expression. 
They also possess an  N-terminal BTB/POZ domain necessary for the interactions with 
other proteins (96). The identification of BTB domain mediated interactions and their 
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networks important to understand their structure-function relationship. In this study, we 
aimed to come up with a systematic assay to screen the interactions among several BTB 
containing transcription factors and the corepressors which are in connection with BTB 
domain containing proteins.  
 
Firstly, we expressed and purified the BTB domains of selected proteins, FAZF-BTB, 
MIZ1-BTB, PATZ1-BTB and PATZ2-BTB, by the use of a bacterial protein expression 
system. For this, a cytoplasmic protein expression protocol was followed. Initially, to be 
sure whether our constructs for these BTB domains express the desired protein or not, we 
performed colony screening method in a small scale and we saw that all tested clones 
were able to express the desired BTB domains accurately.  Next, we continued with the 
large-scale protein expression and purification steps. For purifications, IMAC 
(immobilized metal affinity chromatography) and SEC (size exclusion chromatography) 
protocols were performed respectively. Although cytoplasmic expression was carried out, 
we saw some portions of our proteins in the pellet as well. Fortunately, we obtained 
enough amount of our soluble proteins for the further experimental steps. At this point, 
when we compared the molecular weights of our purified proteins with the expected 
values, we saw that the experimental results were compatible with the calculated versions 
except for MIZ1-BTB, whose molecular weight was lower than expected. This might be 
because of proteolytic modification of this protein during experimental conditions, certain 
physical features of the proteins such as having acidic pI that causes faster migration 
under SDS-PAGE conditions or non-specific protein degradation during experimental 
steps. Furthermore, after IMAC and SEC experiments for PATZ1-BTB, we obtained a 
graph (Figure 4.4D) which has three different peaks. The first peak likely corresponds to 
the homotetramer version of PATZ1 because its molecular weight is compatible with the 
calculated tetramer MW. The second peak likely corresponds to a transitional state 
between possible tetramer and dimer forms of PATZ1. The third peak corresponds to 
homodimeric PATZ1 because its MW is compatible with the calculated MW. For the 
other proteins, there was only one peak and the obtained MWs from these peaks show 
high concordance with the calculated values for homodimeric BTB domains.  
 
Secondly, we wanted to screen homodimerization, heterodimerization, 
homotetramerization and heterotetramerization behaviors of our purified MIZ1-BTB, 
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PATZ1-BTB and PATZ2-BTB proteins and measure their potential interaction affinities 
with surface plasmon resonance (SPR). We covalently immobilized our MIZ1-BTB, 
PATZ1-BTB and PATZ2-BTB domains on the CM5 chip. On this chip, they might be 
anchored either in dimer form or monomer form. Over them, same proteins were passed 
to see possible homodimer/heterodimer/homotetramer/heterotetramer formations.  We 
observed intramolecular interactions between MIZ1 dimers or monomers and PATZ1 
dimers or monomers, but not between PATZ2 dimers or monomers. These interactions 
indicate that MIZ1 and PATZ1 can homotetramerize or homodimerize. Also, preliminary 
results show the presence of an interaction between MIZ1 and PATZ1 dimers, indicating 
the possibility of the presence of MIZ1-PATZ1 heterodimers or heterotetramers. We did 
not observe an interaction between PATZ1 and PATZ2 dimers or monomers, or PATZ2 
and MIZ1 dimers or monomers. The results seem to show concentration-dependent 
interactions; higher the concentration, better the binding. However, the obtained signals 
were not high enough to draw an absolute conclusion about these interactions. The chip 
structure, immobilization methods and multiple cycle kinetic steps should be optimized 
to obtain more representative results and different BTB domains should be used to get a 
picture about these behaviors.  
 
Finally, we set up a fluorescent two hybrid (F2H) assay to assess the homodimerization 
and heterodimerization patterns of selected BTB domains and their interactions with the 
NCOR and SMRT corepressor proteins. For this purpose, we used 11 different BTB 
domains.  These BTB domains were tagged with two different fluorescent tags; TagGFP 
and TagRFP. According to this experimental set up, if there is homodimerization or 
heterodimerization among two differently labelled BTB domains, we will expect to see 
the colocalization of green and red foci at the same spot. Furthermore, the parts of the 
NCOR and SMRT proteins which are responsible for binding to the BTB dimers were 
tagged with BFP fluorescent protein. If there is an interaction between BTB dimers and 
one of these proteins, we will see the colocalization of green, red and blue (or green and 
blue, depending on the type of BTB dimers) foci at the same location.  
 
For these experiments, we used BCL6-BTB as a positive control because according to the 
literature, BCL6 protein is able to homodimerize and the presence of BTB domain is 
sufficient and necessary for homodimerization to take place. Moreover, BCL6 interacts 
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with NCOR and SMRT proteins when a BTB dimer can form (95). Our preliminary 
results related to BCL6-BTB confirmed this; we saw the corresponding colocalization 
patterns for homodimerization and also for interactions with NCOR and SMRT. Next, we 
checked whether BACH1-BTB, BACH2-BTB, KAISO-BTB, LRF-BTB, MIZ1-BTB, 
PATZ1-BTB, PATZ2-BTB and PLZF-BTB domains can homodimerize. We observed 
that all of these except the BACH1-BTB were able to homodimerize. The 
homodimerization patterns were compatible with both the patterns of BCL6-BTB, our 
positive control, and with the literature (97, 98, 51, 66, 90, 71).  In the BACH1-BTB case, 
for dimerization to take place, the kinked N-terminal region (N-hook) at the BTB domain 
is required (89). In our expression system, it is possible that this structure is not formed 
because of the fused fluorescent protein to the N-terminus.  
 
For BTB pairs that interacted, we quantified if the interaction was observed in multiple 
cells/samples. In multiple images acquired from transfected cells, we counted all the cells 
containing green foci. Among these, we identified the ones in which red and green foci 
were colocalized. Using these values, we calculated the percentage of green-foci 
containing cells that also showed colocalization and plotted these values in pie-charts. 
Next, we checked the ability of selected BTB domain proteins to heterodimerize. From 
the literature, we already knew that FAZF and PLZF could heterodimerize and the 
presence of a BTB domain is sufficient for this heterodimerization (43). In our system, 
we did not observe any heterodimerization for these BTB domains, which was not 
compatible with the literature. It is likely that further regions of the BTB domain or 
modifications thereof are required for these interactions. Furthermore, full length LRF 
and BCL6 (with BTB domains and ZF motifs) were shown to associate (32). We did not 
observe any interaction between the BTB domains of these two proteins in our system. 
This failure is likely due to the absence of the DNA binding domains of these proteins 
that likely creates the cellular context of the interaction on the DNA. Moreover, it has 
been observed that, PLZF and BCL6 proteins can heterodimerize and this depends on 
both the interactions between BTB domains and ZF motifs (34). We again did not observe 
any heterodimerization among these two proteins, most likely because our interaction 
system only assesses the interactions of BTB domains. Also, MIZ1 and BCL6 can interact 
to form heterodimers which is only mediated by their BTB domains (62). In our system, 
we did not observe any heterodimerization for these two proteins.  
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Further experiments showed that PATZ1-BACH1 (65) and ZBTB4-MIZ1 (85) can 
interact, dependent on the BTB domains, and also between PATZ1-BACH2, which 
requires both BTB domain and ZF motifs (65). In our experimental set up, we did not 
observe any interactions. For PATZ1-BACH2, this is expected. However, for the rest, the 
results were not compatible with the literature. Due to the restriction of the F2H system 
to test the interaction of only BTB domains, this system may not recapitulate all biological 
interactions between BTB-ZF proteins (see Figure 4.16). Also, there might be additional 
components such as certain regulatory proteins and post-translational modifications 
required for mediating the dimerization process. The only heterodimerization we 
observed was between PATZ1-BTB and PATZ2-BTB. This interaction was documented 
before (71).  
 
Finally, we checked the interactions of the BCL6-BTB and PATZ1-BTB dimers with 
NCOR and SMRT proteins. We could identify the interactions between BCL6-BTB 
dimers and NCOR/SMRT peptides, which we use as a positive control. Next, we assessed 
the interaction between PATZ1-BTB dimers and NCOR/SMRT peptides. Previously, 
PATZ1-BTB and NCOR interactions were demonstrated (66). However, the PATZ1-
SMRT interaction has not yet been documented. Our preliminary results show that 
PATZ1-BTB dimers may interact with both NCOR and SMRT peptides.  
 
For the further identification of the protein-protein interactions of BTB-containing 
transcription factors, other methods can be used as well. For example, förster resonance 
energy transfer (FRET) is a powerful technique for the detection of protein-protein 
interactions both in vivo and in vitro conditions in a direct way. It is based on the fact that 
the bait and prey proteins are fused with compatible donor and acceptor fluorophores and 
there is an energy transition from donor fluorophore to acceptor one when two proteins 
of interest are located 10 nm away from each other and when the donor fluorophore is 
excited. This transfer of photons between donor and acceptor proteins results in the 
fluorescence of the acceptor, calculated as a FRET signal (99). TagBFP-TagGFP2 
(improved version of TagGFP) and TagGFP2-TagRFP pairs give the most efficient FRET 
results among tested Tag fluorescent proteins. In our system, BTB domains were tagged 
with TagGFP and TagRFP and we can use this technology to determine the presence of 
homodimerization/heterodimerization among BTB domains. Furthermore, availability of 
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tetramerization can be checked by our F2H assay. For this purpose, we can tag our BTB 
domains with four different fluorescent proteins such as mTagBFP, TagGFP, TagRFP 
and mRFP1. By transfecting all necessary plasmids into BHK cells, we can observe the 
colocalization of four foci with different colors with the help of live-cell imaging 
microscope and make deductions about their ability to tetramerize. 
 
In conclusion, we generated two different assays to screen for the dimerization and 
tetramerization of BTB domains. Our F2H system is also capable of testing the interaction 
between BTB domains and the corepressors interaction partners. Our interaction systems 
can assess binding both in vitro and in vivo. As a next step, we aim to test the remaining 
BTB domain interactions to complete the interaction matrix of these proteins. 
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APPENDIX A 
 
 
 
Chemicals 
 
Chemicals and Media Components 
2-Mercaptoethanol 
Acetic acid (glacial) 
Acrylamide/Bis-acrylamide (30%) 
Agarose 
Ammonium Persulfate 
Ampicilin Sodium Salt 
Boric Acid 
Chloramphenicol 
Coumaric Acid 
Coomassie Blue Brilliant Blue R 
Distilled Water 
DMEM 
DMSO 
DNA Gel Loading Dye, 6X 
DTT 
EDTA 
Ethanol 
Ethidium Bromide 
Fetal Bovine Serum 
Glycerol 
Glycine 
HBSS 
HEPES 
HisPure Cobalt Superflow Agarose 
Hydrochloric Acid 
Hydrogen peroxide 
Supplier Company 
Sigma, Germany 
Merck Millipore, USA 
Sigma, Germany 
Sigma, Germany 
Sigma, Germany 
Sigma, Germany 
Molekula, France 
Deva, Turkey 
Sigma, Germany 
Sigma, Germany 
Merck Millipore, USA 
Thermo Fischer Scientific, USA 
Sigma, Germany 
NEB, USA 
Fermentas, USA 
Sigma, Germany 
Sigma, Germany 
Sigma, Germany 
Thermo Fischer Scientific, USA 
Sigma, Germany 
Sigma, Germany 
Thermo Fischer Scientific, USA 
Sigma, Germany 
Thermo Fischer Scientific, USA 
Sigma, Turkey 
Sigma, Turkey 
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Imidazole  
IPTG  
Isopropanol  
Kanamycin Sulfate  
LB Agar  
LB Broth  
L-Glutathione reduced  
Methanol  
PBS  
Penicillin/Streptomycin  
PIPES  
Potassium Acetate  
Protease Tablets (EDTA-free) 
RNase A  
SDS  
Sodium Azide  
Sodium Chloride 
Sodium Hydroxide  
TEMED  
TCEP  
Terrific Broth  
Tris Base  
Tris Hydrochloride  
Trypan Blue Solution   
Tween20  
 
 
 
 
 
 
 
 
Sigma, Germany 
Fermentas, USA 
Sigma, Germany 
Thermo Fischer Scientific, USA 
Sigma, Germany 
Invitrogen, USA 
Sigma, Germany  
Sigma, Germany 
Thermo Fischer Scientific, USA  
Thermo Fischer Scientific, USA  
Sigma, Germany 
Merck Millipore, USA 
Roche, Germany 
Roche, Germany 
Sigma, Germany 
Amresco, USA 
Amresco, USA 
Sigma, Germany 
AppliChem, Germany 
Sigma, Germany 
Sigma, Germany 
Sigma, Germany 
Amresco, USA 
Thermo Fischer Scientific, USA 
Sigma, Turkey 
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APPENDIX B 
 
 
 
Equipment 
 
Equipment Supplier  
Autoclave  
Balance  
Centrifuge  
 
 
 
 
 
CO2 Incubator  
Column  
 
 
 
Countless II Automated Cell Counter  
Deepfreeze  
 
 
Electrophoresis Apparatus  
 
Filters (0.22µm and 0.45µm)  
Freezing Container 
 
Gel Documentation 
Heater 
 
Hemocytometer  
Company 
HiClave HV-110, Hirayama, Japan 
Isolab, Germany 
5418R Eppendorf, Germany 
5702 Eppendorf, Germany 
5415R Eppendorf, Germany 
Allegra X-15R, Beckman Coulter, USA 
Sorvall Lynx 6000, Thermo Scientific, 
USA 
Binder, Germany 
HiLoad 16/60 Superdex p75 GE 
Healthcare Life Sciences, USA 
Superdex 200 Increase 5/150 GL 
Superdex 200 Increase 10/300 GL 
Thermo Fischer Scientific, USA 
-80°C, Forma 88000 Series, Thermo 
Fischer Scientific, USA 
-20°C, Bosch, Germany 
VWR, USA 
BIORAD, USA 
Merk Millipore, USA 
Mr. Frosty, Thermo Fischer Scientific, 
USA 
Gel Doc EZ, Biorad, USA 
Thermomixer Comfort Eppendorf, 
Germany 
Neubauer Improved, Isolab, Germany 
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Ice Machine  
Incubator Shaker  
 
Laminar Flow  
 
Liquid Nitrogen  
Magnetic Stirrer 
Microliter Pipettes  
Microscope  
 
Microwave Oven  
pH Meter  
Refrigerator  
 
 
 
RTCA system 
Sonicator 
Spectrophotometer 
 
 
 
Surface Plasmon Resonance System 
 
Thermal Cycler 
 
Vortex 
Water Bath 
 
 
 
 
 
AF20, Scotsman Inc., USA 
Innova 44, New Brunswick Scientific 
USA 
HeraSafe HS15, Heraeus, Germany 
HeraSafe HS12, Heraeus, Germany 
Taylor-Wharton, 300RS, USA 
SB162, Stuart, UK 
Thermo Fischer Scientific, USA 
Primovert, Zeiss, Germany 
CK40, Olympus, Japan 
Bosch, Germany 
SevenCompact, Mettler Toledo, USA 
Bosch, Germany 
Arcelik, Turkey 
Panasonic, Japan 
Thermo Fischer Scientific, USA 
ACEA Biosciences, USA 
Qsonica Q500, USA 
NanoDrop 2000, Thermo Fischer 
Scientific, USA 
Ultrospec 2100 pro, Amersham 
Biosciences, UK 
BIACORE T200, GE Healthcare Life 
Sciences, USA 
C1000 Touch, Biorad, USA 
PTC-200, MJ Reseach Inc., Canada 
VWR, USA 
Innova 3100, New Brunswick Scientific, 
USA
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APPENDIX C 
 
 
 
Molecular Biology Kits 
 
GenElute Agarose Spin Columns  
NucleoSpin Gel and PCR Clean-up  
Plasmid DNA purification 
(NucleoBond® Xtra Midi / Maxi) 
ZymoPure Plasmid Maxiprep Kit  
 
Sigma-Aldrich, USA 
Macherey-Nagel, USA 
Macherey-Nagel, USA 
 
Zymo Research, USA 
 
 
 
APPENDIX D 
 
 
 
DNA and Protein Molecular Weight Marker 
 
                                                         
 
 
 
 
Figure D1. GeneRuler DNA 
Ladder Mix (SM0331), Thermo 
Fischer Scientific, USA 
 
Figure D2. Color Prestained 
Protein Standard, Broad Range 
(11-245 kDa) (P7712S), New 
England Biolabs 
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APPENDIX E 
 
 
 
Plasmid Maps 
 
 
 
Figure F1. The plasmid map of pET-47b(+) 
 
 
 
 
  
 
Figure F2. The plasmid map of pcDNA3.1 Myc His B (-) 
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Figure F3. The plasmid map of pcDNA3-GFP 
 
 
 
 
 
Figure F4. The plasmid map of pcDNA3.1 Myc His B (-)-BFP-NLS 
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Figure F5. The plasmid map of pCDNA3.1/myc-His (-) B-BFP-oligo1-NCOR 
 
 
 
 
 
Figure F6. The plasmid map of pCDNA3.1/myc-His (-) B-BFP-oligo1-SMRT 
 
 
